{"id":378515,"date":"2025-11-04T09:22:00","date_gmt":"2025-11-04T01:22:00","guid":{"rendered":"https:\/\/pingtungtimes.com.tw\/?p=378515"},"modified":"2025-11-04T09:22:00","modified_gmt":"2025-11-04T01:22:00","slug":"%e3%80%902025-ash%e3%80%91%e4%ba%9e%e7%9b%9b%e9%86%ab%e8%97%a5%e8%80%90%e7%ab%8b%e5%85%8b%e5%a4%9a%e9%a0%85%e7%a0%94%e7%a9%b6%e5%85%a5%e9%81%b8%ef%bc%8cpolaris-1%e7%a0%94%e7%a9%b6%e6%95%b8","status":"publish","type":"post","link":"https:\/\/pingtungtimes.com.tw\/?p=378515","title":{"rendered":"\u30102025 ASH\u3011\u4e9e\u76db\u91ab\u85e5\u8010\u7acb\u514b\u00ae\u591a\u9805\u7814\u7a76\u5165\u9078\uff0cPOLARIS-1\u7814\u7a76\u6578\u64da\u9996\u6b21\u767c\u5e03"},"content":{"rendered":"
\n\n\n\n
<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde<\/span>2025\u5e7411\u67084\u65e5<\/span> \/\u7f8e\u901a\u793e\/ —\u00a0\u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae<\/sup>\uff09\u6709\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c8\u5e74\u5165\u9078ASH\u5e74\u6703\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u00ae<\/sup>\u3001\u5229\u751f\u59a5\u00ae<\/sup>\u3001APG-5918\uff09\u6709\u591a\u9805\u81e8\u5e8a\u548c\u81e8\u5e8a\u524d\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5176\u4e2d\u4e00\u9805\u7372\u53e3\u982d\u5831\u544a\u3002<\/p>\n

\n<\/p><\/div>\n

\u8010\u7acb\u514b\u00ae<\/sup>\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u3002\u5176\u5728\u4e2d\u570b\u7684\u5546\u696d\u5316\u63a8\u5ee3\u7531\u4e9e\u76db\u91ab\u85e5\u548c\u4fe1\u9054\u751f\u7269\u5171\u540c\u8ca0\u8cac\u3002\u516c\u53f8\u5c07\u5728\u6b64\u6b21ASH\u5e74\u6703\u4e0a\uff0c\u9996\u6b21\u767c\u5e03\u8010\u7acb\u514b\u00ae<\/sup>\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684\u5168\u7403III\u671f\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff09\u6700\u65b0\u6578\u64da\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae<\/sup>\u6cbb\u7642\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5CML-CP\u60a3\u8005\u7684\u96a8\u6a5f\u5c0d\u7167\u6ce8\u518aII\u671f\u7814\u7a76\u76844\u5e74\u96a8\u8a2a\u6578\u64da\u3001\u548c\u5176\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCML-CP\u60a3\u8005\u7684\u6578\u64da\u4e5f\u5c07\u5728\u6b64\u6b21\u6703\u8b70\u4e0a\u66f4\u65b0\u3002<\/p>\n

\u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u6703\u662f\u5168\u7403\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u5b78\u8853\u76db\u6703\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u84cb\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7642\u7814\u7a76\u3002\u7b2c67\u5c46ASH\u5e74\u6703\u5c07\u65bc\u7576\u5730\u6642\u95932025\u5e7412\u67086\u65e5\u81f39\u65e5\u9593\u5728\u7f8e\u570b\u4f5b\u7f85\u88e1\u9054\u5dde\u5967\u862d\u591a\u5e02\u4ee5\u7dda\u4e0b\u7d50\u5408\u7dda\u4e0a\u7684\u5f62\u5f0f\u8209\u884c\u3002<\/p>\n

\u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb<\/b>\u8868\u793a\uff1a\u300c\u4eca\u5e74\u5c07\u662f\u8010\u7acb\u514b\u00ae<\/sup>\u9023\u7e8c\u7b2c8\u5e74\u5728ASH\u5e74\u6703\u4e0a\u5c55\u793a\u6700\u65b0\u81e8\u5e8a\u9032\u5c55\uff0c\u518d\u4e00\u6b21\u9ad4\u73fe\u4e86\u570b\u969b\u8840\u6db2\u5b78\u754c\u5c0d\u8010\u7acb\u514b\u00ae<\/sup>\u7684\u5de8\u5927\u8a8d\u53ef\u3002\u76ee\u524d\uff0c\u8a72\u54c1\u7a2e\u67093\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u3002\u6b64\u5916\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u91cd\u9ede\u54c1\u7a2e\u6709\u591a\u9805\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5145\u5206\u986f\u73fe\u4e86\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u548c\u958b\u767c\u5be6\u529b\u3002\u6211\u5011\u671f\u5f85\u5728\u5f8c\u7e8c\u6703\u8b70\u671f\u9593\u8207\u5927\u5bb6\u5206\u4eab\u76f8\u95dc\u7814\u7a76\u7684\u8a73\u5be6\u6578\u64da\u3002\u672a\u4f86\uff0c\u4e9e\u76db\u91ab\u85e5\u5c07\u9032\u4e00\u6b65\u52a0\u901f\u63a8\u9032\u81e8\u5e8a\u958b\u767c\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d<\/p>\n

ASH 2025\u4e9e\u76db\u91ab\u85e5\u7522\u54c1\u76f8\u95dc\u7814\u7a76\u4e00\u89bd\uff1a<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\u5c55\u793a\u5f62\u5f0f<\/b><\/span><\/p>\n<\/td>\n

\n

\u54c1\u7a2e<\/b><\/span><\/p>\n<\/td>\n

\n

\u6458\u8981\u6a19\u984c<\/b><\/span><\/p>\n<\/td>\n

\n

\u7de8\u865f<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u53e3\u982d\u5831\u544a<\/span><\/p>\n<\/td>\n

\n

\u5229\u6c99\u6258\u514b\u62c9<\/span><\/p>\n

\uff08APG-2575\uff09<\/span><\/p>\n<\/td>\n

\n

Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed\/refractory chronic <\/span><\/p>\n

lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who had failed Bruton’s tyrosine kinase inhibitors (BTKis)<\/span><\/p>\n

\u4e00\u9805\u95dc\u65bc\u5229\u6c99\u6258\u514b\u62c9\u55ae\u85e5\u6cbb\u7642\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08BTKi\uff09\u6cbb\u7642\u5931\u6557\u7684\u5fa9\u767c\/\u96e3\u6cbb\u6027\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/<\/span><\/p>\n

\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u6ce8\u518a\u6027II\u671f\u7814\u7a76\u7d50\u679c<\/span><\/p>\n<\/td>\n

\n

88<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u58c1\u5831\u5c55\u793a<\/span><\/p>\n<\/td>\n

\n

\u5229\u6c99\u6258\u514b\u62c9<\/span><\/p>\n

\uff08APG-2575\uff09<\/span><\/p>\n<\/td>\n

\n

Results of the APG2575AU101 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) <\/span><\/p>\n

or prior venetoclax\u2013exposed myeloid malignancies<\/span><\/p>\n

\u5229\u6c99\u6258\u514b\u62c9\u806f\u5408\u963f\u624e\u80de\u7518\u6cbb\u7642\u521d\u6cbb\u6216\u65e2\u5f80\u4f7f\u7528\u904e\u7dad\u5948\u6258\u514b\u7684\u9ad3\u7cfb\u816b\u7624\u7684\u81e8\u5e8a\u7814\u7a76\uff08APG2575AU101\uff09\u7d50\u679c<\/span><\/p>\n<\/td>\n

\n

1641<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n

\uff08HQP1351\uff09<\/span><\/p>\n<\/td>\n

\n

Results of POLARIS-1, a global phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with <\/span><\/p>\n

newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)<\/span><\/p>\n

\u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684<\/span><\/p>\n

\u5168\u7403III\u671f\u7814\u7a76POLARIS-1\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c<\/span><\/p>\n<\/td>\n

\n

1574<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase <\/span><\/p>\n

chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations<\/span><\/p>\n

\u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u60272\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08CML-CP\uff09\uff0c<\/span><\/p>\n

\u5305\u62ec\u7121T315I\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08BAT\uff09\uff1a4\u5e74\u96a8\u8a2a\u671f<\/span><\/p>\n<\/td>\n

\n

3788<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML)<\/span><\/p>\n

\u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u6578\u64da<\/span><\/p>\n<\/td>\n

\n

3782<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Preclinical and clinical Study of olverembatinib in patients with myeloid\/lymphoid neoplasms with FGFR1 rearrangement<\/span><\/p>\n

\u5967\u96f7\u5df4\u66ff\u5c3c\u7684\u81e8\u5e8a\u524d\u8207\u81e8\u5e8a\u7814\u7a76\uff1a\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\/\u6dcb\u5df4\u816b\u7624<\/span><\/p>\n<\/td>\n

\n

1979<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: <\/span><\/p>\n

First real-world practice report<\/span><\/p>\n

\u5967\u96f7\u5df4\u66ff\u5c3c\u4ecb\u5c0e\u7684\u6df1\u5ea6\u7de9\u89e3\u63d0\u5347\u7570\u57fa\u56e0\u5e72\u7d30\u80de\u79fb\u690d\u5728\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u6025\u8b8a\u671f\u60a3\u8005\u4e2d\u7684\u7642\u6548\uff1a<\/span><\/p>\n

\u9996\u4efd\u771f\u5be6\u4e16\u754c\u5be6\u8e10\u5831\u544a<\/span><\/p>\n<\/td>\n

\n

1999<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: <\/span><\/p>\n

A prospective, multicenter, control trial<\/span><\/p>\n

\u5c0d\u65bc\u65e2\u5f80\u63a5\u53d7\u904e\u81f3\u5c11\u5169\u7a2eTKI\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u6027\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\uff0c\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u8207\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a<\/span><\/p>\n

\u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u5c0d\u7167\u7814\u7a76<\/span><\/p>\n<\/td>\n

\n

3779<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Clinical and molecular features associated with glucolipid metabolic disorders and cardio-\/cerebro-vascular adverse events in <\/span><\/p>\n

CML patients receiving olverembatinib therapy<\/span><\/p>\n

\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u60a3\u8005\u51fa\u73fe\u7cd6\u8102\u4ee3\u8b1d\u7d0a\u4e82\u53ca\u5fc3\/\u8166\u8840\u7ba1\u4e0d\u826f\u4e8b\u4ef6\u7684<\/span><\/p>\n

\u81e8\u5e8a\u8207\u5206\u5b50\u7279\u5f81<\/span><\/p>\n<\/td>\n

\n

5561<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

APG-5918<\/span><\/p>\n<\/td>\n

\n

Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with <\/span><\/p>\n

IMiDs\/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM)<\/span><\/p>\n

\u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\uff08EED\uff09\u6291\u5236\u5291APG-5918\u55ae\u85e5\u5728\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d\u4e86\u514d\u75ab\u8abf\u7bc0\u85e5\u7269\uff08IMiD\uff09\u8010\u85e5\u6027\u4e26\u986f\u793a\u4e86<\/span><\/p>\n

\u8207IMiDs\/Cereblon E3\u9023\u63a5\u9176\u8abf\u7bc0\u5291\uff08CELMoDs\uff09\u7684\u5354\u540c\u6548\u61c9<\/span><\/p>\n<\/td>\n

\n

1528<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u5728\u7dda\u767c\u5e03<\/span><\/p>\n<\/td>\n

\n

\u5967\u96f7\u5df4\u66ff\u5c3c<\/span><\/p>\n

\uff08HQP1351\uff09<\/span><\/p>\n<\/td>\n

\n

Single CAR-t infusion during front-line consolidation induces deep and sustained remission
in newly diagnosed adult ph+b- ALL: A prospective phase 2 study<\/span><\/p>\n

\u5c0d\u65bc\u65b0\u8a3a\u65b7\u7684\u6210\u4ebaPh\u967d\u6027B-ALL\u60a3\u8005\uff0c\u5728\u4e00\u7dda\u978f\u56fa\u6cbb\u7642\u968e\u6bb5\u9032\u884c\u55ae\u6b21CAR-T\u7d30\u80de\u8f38\u6ce8\uff0c\u53ef\u8a98\u5c0e\u6df1\u5ea6\u4e14\u6301\u4e45\u7684\u7de9\u89e3\uff1a\u4e00\u9805\u524d\u77bb\u6027II\u671f\u7814\u7a76\u3002<\/span><\/p>\n<\/td>\n

\n

442<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u5229\u6c99\u6258\u514b\u62c9<\/span><\/p>\n

\uff08APG-2575\uff09<\/span><\/p>\n<\/td>\n

\n

BCL-2 inhibition in North American adult T-cell leukemia\/lymphoma: Preclinical insights
and early clinical outcomes<\/span><\/p>\n

BCL-2\u6291\u5236\u5291\u5728\u5317\u7f8e\u6210\u4ebaT\u7d30\u80de\u767d\u8840\u75c5\/\u6dcb\u5df4\u7624\u4e2d\u7684\u9776\u5411\u6cbb\u7642\uff1a\u81e8\u5e8a\u524d\u7814\u7a76\u8207\u65e9\u671f\u81e8\u5e8a\u7d50\u679c<\/span><\/p>\n<\/td>\n

\n

3304<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n

\u5967\u96f7\u5df4\u66ff\u5c3c\u5165\u90782025 ASH\u5e74\u6703\u7684\u4e3b\u8981\u7814\u7a76\u6458\u8981\u5982\u4e0b\uff1a\uff08\u5229\u6c99\u6258\u514b\u62c9\u5165\u9078ASH\u5e74\u6703\u7684\u6458\u8981\u8a73\u7d30\u4fe1\u606f\u53c3\u898b\u540c\u671f\u767c\u5e03\u7684\u53e6\u4e00\u7bc7\u65b0\u805e\u7a3f\uff09<\/p>\n

Results of POLARIS-1, a global Phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia<\/span> chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)
<\/b>\u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08<\/b>ND<\/b>\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08<\/b>Ph+<\/b>\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08<\/b>ALL<\/b>\uff09\u60a3\u8005\u7684\u5168\u7403<\/b>III<\/b>\u671f\u7814\u7a76<\/b>POLARIS-1<\/b>\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c
<\/b>\u5c55\u793a\u5f62\u5f0f<\/b>\uff1a\u58c1\u5831\u5c55\u793a
\u6458\u8981\u7de8\u865f<\/b>\uff1a1574
\u5206\u6703\u5834<\/b>\uff1a613. \u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u540c\u7a2e\u79fb\u690d\u4ee5\u5916\u7684\u7642\u6cd5\uff1a\u58c1\u5831\u5c55\u793aI
\u5831\u544a\u6642\u9593<\/b>\uff1a
2025\u5e7412\u67086\u65e5\uff0c\u661f\u671f\u516d\uff0c\u4e0b\u534817:30 \u2013 19:30\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff09
2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0a\u53486:30 \u2013 8:30\uff08\u5317\u4eac\u6642\u9593\uff09
\u7b2c\u4e00\u4f5c\u8005<\/b>\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388
\u5831\u544a\u4eba<\/b>\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388
\u6838\u5fc3\u8981\u9ede<\/b>\uff1a
\u8a72\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff1bNCT06051409\uff09\u70ba\u4e00\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u5728\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff1b\u9006\u8f49\u9304qPCR\u65b9\u6cd5\u6aa2\u6e2cBCR-ABL1\/ABL1\u22640.01%\uff09\u9670\u6027\u7387\u3002<\/p>\n

\u7642\u6548\u6578\u64da<\/u>\uff1a<\/p>\n

    \n
  • \u622a\u81f32025\u5e747\u670818\u65e5\uff0c\u572853\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c50\u4f8b\u60a3\u8005\uff0894.3%\uff09\u5728\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5be6\u73fe\u4e86\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u6216CR\u4f34\u4e0d\u5b8c\u5168\u8840\u6db2\u5b78\u6062\u5fa9\uff0c\u6700\u4f73MRD\u9670\u6027\u7387\u548cMRD\u9670\u6027CR\u7387\u5206\u5225\u70ba66.0%\u548c64.2%\u3002<\/li>\n
  • IKZF1plus<\/sup>\uff08\u5c24\u5176\u5408\u4e26BTG1\u7f3a\u5931\uff09\u662fB-ALL\u516c\u8a8d\u7684\u9ad8\u5371\u56e0\u7d20\uff0c\u5e38\u5c0e\u81f4\u5316\u7642\u8010\u85e5\u8207\u9ad8\u5fa9\u767c\u3002\u5728\u672c\u7814\u7a7610\u4f8b\u651c\u5e36\u6b64\u7279\u5f81\u7684\u60a3\u8005\u4e2d\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642\u7684\u5206\u5b50\u5b78\u7de9\u89e3\u7387\u9ad8\u905490%\uff089\/10\uff09\u3002<\/li>\n<\/ul>\n

    \u5b89\u5168\u6027\u6578\u64da<\/u>\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5291\u91cf\u5316\u7642\u8010\u53d7\u6027\u826f\u597d\u3002\u5e38\u898b\u7684\uff08\u767c\u751f\u7387>15%\uff093\u7d1a\u6216\u4ee5\u4e0a\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u70ba\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\u75c7\uff0863.6%\uff09\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\uff0856.4%\uff09\u3001\u767d\u7d30\u80de\u6e1b\u5c11\u75c7\uff0854.5%\uff09\u3001\u8ca7\u8840\uff0849.1%\uff09\u3001\u80ba\u708e\uff0830.9%\uff09\u3001\u4f4e\u9240\u8840\u75c7\uff0820%\uff09\u548c\u809d\u529f\u80fd\u7570\u5e38\uff0816.4%\uff09\u3002<\/p>\n

    \u7d50\u8ad6<\/u>\uff1a
    \u5728\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6cbb\u7642\u7684\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\uff0c\u81f3\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642MRD\u9670\u6027CR\u7387\u905464.2%\uff0c\u4e26\u986f\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u3002<\/p>\n

    Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations
    <\/b>\u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u6027<\/b>2<\/b>\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08<\/b>HQP1351<\/b>\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08<\/b>TKI<\/b>\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08<\/b>CML-CP<\/b>\uff09\uff0c\u5305\u62ec\u7121<\/b>T315I<\/b>\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08<\/b>BAT<\/b>\uff09\uff1a<\/b>4<\/b>\u5e74\u96a8\u8a2a\u671f
    <\/b>\u5c55\u793a\u5f62\u5f0f<\/b>\uff1a\u58c1\u5831\u5c55\u793a
    \u6458\u8981\u7de8\u865f<\/b>\uff1a3788
    \u5206\u6703\u5834<\/b>\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII
    \u5831\u544a\u6642\u9593<\/b>\uff1a
    2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 \u2013 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff09
    2025\u5e7412\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 \u2013 9:00\uff08\u5317\u4eac\u6642\u9593\uff09
    \u7b2c\u4e00\u4f5c\u8005<\/b>\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388
    \u5831\u544a\u4eba<\/b>\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388
    Highlights:
    <\/b>\u6838\u5fc3\u8981\u9ede<\/b>\uff1a<\/p>\n

      \n
    • \u8a72\u7814\u7a76\uff08NCT04126681\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u96a8\u6a5f\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7684\u95dc\u9375\u6ce8\u518aII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u672c\u5831\u544a\u70ba\u4e00\u98052023ASH\u5e74\u6703\u53e3\u982d\u5831\u544a\u7684\u7814\u7a76\u66f4\u65b0\u6578\u64da\u3002\u622a\u81f32025\u5e741\u670813\u65e5\uff0c\u5171\u6709144\u4f8bCML-CP\u60a3\u8005\u5165\u7d44\uff0c\u5176\u4e2d105\u4f8b\u70ba\u4e0d\u4f34T315I\u7a81\u8b8a\u60a3\u8005\u3002<\/li>\n
    • \u5728\u672c\u7814\u7a76\u4e2d\uff0c\u60a3\u8005\u88ab\u6309\u71672:1 \u6bd4\u4f8b\u96a8\u6a5f\u5206\u7d44\u9032\u5165\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548c\u7814\u7a76\u8005\u6c7a\u5b9a\u7684\u73fe\u6709\u6700\u4f73\u6cbb\u7642\uff08BAT\uff09\u5c0d\u7167\u7d44\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u7121\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u3002<\/li>\n<\/ul>\n

      \u7642\u6548\u6578\u64da<\/u>\uff1a<\/p>\n

        \n
      • \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u986f\u8457\u9577\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CMP-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba21.22\u500b\u6708\u548c2.86\u500b\u6708\uff08P <\/i>< 0.001\uff09\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba11.96 \u548c3.14\u500b\u6708\uff08P<\/i> = 0.0159\uff09\u3002<\/li>\n
      • \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u5176\u4ed6\u7642\u6548\u6307\u6a19\u986f\u8457\u9ad8\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u5b8c\u5168\u8840\u6db2\u5b78\u7de9\u89e3(CHR)\u7387\u5206\u5225\u70ba85% \u548c34.8%\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u5206\u5225\u70ba37.5%\u548c18.9%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u5206\u5225\u70ba29.5%\u548c8.1%\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0cCHR\u5206\u5225\u70ba82.1% \u548c50.0%\uff0cCCyR\u5206\u5225\u70ba25.8%\u548c20.7%\uff0cMMR\u5206\u5225\u70ba16.1%\u548c 10.3%\u3002<\/li>\n<\/ul>\n

        \u5b89\u5168\u6027\u6578\u64da<\/u>\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u5728\u4f34\u6216\u4e0d\u4f34T315I\u7a81\u8b8a\u7684CML-CP\u60a3\u8005\u4e2d\u5747\u5c55\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u6db2\u5b78\u6bd2\u6027\u3002<\/p>\n

        \u7d50\u8ad6<\/u>\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6cbb\u7642\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u53d7\u8a66\u8005\uff0c\u5305\u62ec\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u6642\uff0c\u8f03BAT\u6cbb\u7642\u7d44\u5c55\u793a\u51fa\u660e\u986f\u6cbb\u7642\u512a\u52e2\u3002<\/p>\n

        Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML)
        <\/b>\u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642<\/b>CP-CML<\/b>\u60a3\u8005\u6578\u64da
        <\/b>\u5c55\u793a\u5f62\u5f0f\uff1a<\/b>\u58c1\u5831\u5c55\u793a
        \u6458\u8981\u7de8\u865f\uff1a<\/b>3782
        \u5206\u6703\u5834\uff1a<\/b>632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII
        \u5831\u544a\u6642\u9593\uff1a
        <\/b>2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 – 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff09
        2025\u5e74 12\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 – 9:00\uff08\u5317\u4eac\u6642\u9593\uff09
        \u7b2c\u4e00\u4f5c\u8005<\/b>\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388
        \u5831\u544a\u4eba<\/b>\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388
        \u6838\u5fc3\u8981\u9ede<\/b>\uff1a
        \u8a72\u7814\u7a76\uff08ChiCTR2200061655\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u9694\u65e5\u53e3\u670d40mg\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u65e2\u5f80\u4f7f\u7528\u904e\u4e00\u7a2eTKI\u6cbb\u7642\u5f8c\u8010\u85e5\u6216\u4e0d\u8010\u53d7\uff08\u5305\u62ec\u4f0a\u99ac\u66ff\u5c3c\u3001\u6c1f\u99ac\u66ff\u5c3c\u3001\u5c3c\u6d1b\u66ff\u5c3c\u53ca\u9054\u6c99\u66ff\u5c3c\u7b49\uff09\u7684\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u622a\u81f32025\u5e747\u670824\u65e5\uff0c\u5171\u5165\u7d44\u975eT315I \u7a81\u8b8a\u7684CP-CML \u60a3\u800547\u4f8b\u3002<\/p>\n

        \u7642\u6548\u6578\u64da<\/u>\uff1a<\/p>\n

          \n
        • \u622a\u81f32025\u5e747\u670824\u65e5\uff0c39\u4f8b\uff0883.0%\uff09\u60a3\u8005\u63a5\u53d7\u4e86\u81f3\u5c111\u6b21\u7642\u6548\u8a55\u4f30\uff0c36\u4f8b\uff0876.6%\uff09\u63a5\u53d7\u4e86\u81f3\u5c112\u6b21\u7642\u6548\u8a55\u4f30\uff0c34\u4f8b\uff0872.3%\uff09\u63a5\u53d7\u4e86\u81f3\u5c113\u6b21\u7642\u6548\u8a55\u4f30\u30022\u4f8b\u60a3\u8005\u5c1a\u672a\u9032\u884c\u9996\u6b21\u7642\u6548\u8a55\u4f30\u3002<\/li>\n
        • \u81f3\u622a\u6b62\u65e5\u671f\uff0c71.8%\uff0828\/39\uff09\u7684\u60a3\u8005\u7372CCyR\uff0c43.6%\uff0817\/39\uff09\u7372MMR\u3002\u7b2c6\u30019\u300112\u300115\u300118\u300121\u300124\u500b\u5468\u671f\u8a55\u4f30\u7684CCyR\u7387\u548cMMR\u7387\u5206\u5225\u70ba54.3%\u548c25.7%\u300166.7%\u548c33.3%\u300174.2%\u548c35.5%\u300184.6%\u548c46.2%\u300185.7% \u548c 47.6%\u300190.0% \u548c 60.0%\u300189.5% \u548c 57.9%\u3002\u63d0\u793a\u7642\u6548\u96a8\u7528\u85e5\u6642\u9593\u5ef6\u9577\u800c\u7de9\u89e3\u9010\u6f38\u52a0\u6df1\u3002<\/li>\n
        • \u572839\u4f8b\u7642\u6548\u53ef\u8a55\u4f30\u7684\u60a3\u8005\u4e2d\uff0c\u670930\u4f8b\u60a3\u8005\u65e2\u5f80\u4ee5\u4e8c\u4ee3TKI\u4f5c\u70ba\u4e00\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d76.7%\uff0823\/30\uff09\u7372\u5f97CCyR\uff0c43.3%\uff0813\/30\uff09\u7372\u5f97MMR\uff1b\u5728\u65e2\u5f80\u63a5\u53d7\u4f0a\u99ac\u66ff\u5c3c\u6cbb\u7642\u76849\u4f8b\u60a3\u8005\u4e2d\uff0c55.6%\uff085\/9\uff09\u7372\u5f97CCyR\uff0c44.4%\uff084\/9\uff09\u7372\u5f97MMR\u3002<\/li>\n<\/ul>\n

          \u5b89\u5168\u6027\u6578\u64da<\/u>\uff1a\u4e2d\u4f4d\uff08\u5340\u9593\uff09\u6cbb\u7642\u6642\u959316.0\uff081-18\uff09\u500b\u6708\u3002\u5171\u670942\u4f8b\uff0889.4%\uff09\u60a3\u8005\u767c\u751f\u4e86\u4efb\u4f55\u7d1a\u5225\u7684\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u4e8b\u4ef6\uff08TRAEs\uff09\uff0c\u5176\u4e2d21\u4f8b\uff0844.7%\uff09\u767c\u751f\u4e86\u22653\u7d1aTRAEs\uff0c6\u4f8b\uff0812.8%\uff09\u767c\u751f\u4e86\u8207\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dc\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\uff08SAEs\uff09\u3002\u22653\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u53cd\u61c9\u5305\u62ec\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.6%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0825.5%\uff09\u548c\u8ca7\u8840\uff088.5%\uff09\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dcSAEs\u5305\u62ec\u8840\u5c0f\u677f\u8a08\u6578\u6e1b\u5c11\uff086.4%\uff09\u3001\u8ca7\u8840\u3001\u9aa8\u9ad3\u6291\u5236\u548c\u767c\u71b1\uff08\u54042.1%\uff09\u3002\u7121\u6b7b\u4ea1\u5831\u544a\u3002<\/p>\n

          \u7d50\u8ad6<\/u>\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u80fd\u70ba\u4e8c\u7ddaCP-CML\u60a3\u8005\u63d0\u4f9b\u4e00\u7a2e\u5b89\u5168\u6709\u6548\u7684\u6cbb\u7642\u9078\u64c7\uff0c\u5c24\u5176\u662f\u5c0d\u65bc\u4e00\u7dda\u4f7f\u7528\u4e8c\u4ee3\u00a0TKIs\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\u3002<\/p>\n

          \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5<\/b><\/p>\n

          \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002<\/p>\n

          \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c\u00a0MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002<\/p>\n

          \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae<\/sup>\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae<\/sup>\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae<\/sup>\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002<\/p>\n

          \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae<\/sup>\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u65e2\u5f80\u7d93\u904e\u81f3\u5c11\u5305\u542b\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u4e00\u7a2e\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae<\/sup>\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u3001\u6b50\u6d32EMA\u8207\u4e2d\u570bCDE\u540c\u6b65\u6279\u51c6\u958b\u5c55\u7684\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff09\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002<\/p>\n

          \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u7cfb\u3002<\/p>\n

          \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002<\/p>\n

          \u524d\u77bb\u6027\u8072\u660e<\/b><\/p>\n

          \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002<\/p>\n

          \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002<\/p>\n

          \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

          \u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607…<\/p>\n","protected":false},"author":16,"featured_media":378516,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[40567],"tags":[],"class_list":["post-378515","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-40567"],"acf":[],"yoast_head":"\n\u30102025 ASH\u3011\u4e9e\u76db\u91ab\u85e5\u8010\u7acb\u514b\u00ae\u591a\u9805\u7814\u7a76\u5165\u9078\uff0cPOLARIS-1\u7814\u7a76\u6578\u64da\u9996\u6b21\u767c\u5e03 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831<\/title>\n<meta name=\"description\" content=\"\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2025\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ --\u00a0\u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u6709\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c8\u5e74\u5165\u9078ASH\u5e74\u6703\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u00ae\u3001\u5229\u751f\u59a5\u00ae\u3001APG-5918\uff09\u6709\u591a\u9805\u81e8\u5e8a\u548c\u81e8\u5e8a\u524d\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5176\u4e2d\u4e00\u9805\u7372\u53e3\u982d\u5831\u544a\u3002 \u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u3002\u5176\u5728\u4e2d\u570b\u7684\u5546\u696d\u5316\u63a8\u5ee3\u7531\u4e9e\u76db\u91ab\u85e5\u548c\u4fe1\u9054\u751f\u7269\u5171\u540c\u8ca0\u8cac\u3002\u516c\u53f8\u5c07\u5728\u6b64\u6b21ASH\u5e74\u6703\u4e0a\uff0c\u9996\u6b21\u767c\u5e03\u8010\u7acb\u514b\u00ae\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684\u5168\u7403III\u671f\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff09\u6700\u65b0\u6578\u64da\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5CML-CP\u60a3\u8005\u7684\u96a8\u6a5f\u5c0d\u7167\u6ce8\u518aII\u671f\u7814\u7a76\u76844\u5e74\u96a8\u8a2a\u6578\u64da\u3001\u548c\u5176\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCML-CP\u60a3\u8005\u7684\u6578\u64da\u4e5f\u5c07\u5728\u6b64\u6b21\u6703\u8b70\u4e0a\u66f4\u65b0\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u6703\u662f\u5168\u7403\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u5b78\u8853\u76db\u6703\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u84cb\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7642\u7814\u7a76\u3002\u7b2c67\u5c46ASH\u5e74\u6703\u5c07\u65bc\u7576\u5730\u6642\u95932025\u5e7412\u67086\u65e5\u81f39\u65e5\u9593\u5728\u7f8e\u570b\u4f5b\u7f85\u88e1\u9054\u5dde\u5967\u862d\u591a\u5e02\u4ee5\u7dda\u4e0b\u7d50\u5408\u7dda\u4e0a\u7684\u5f62\u5f0f\u8209\u884c\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u4eca\u5e74\u5c07\u662f\u8010\u7acb\u514b\u00ae\u9023\u7e8c\u7b2c8\u5e74\u5728ASH\u5e74\u6703\u4e0a\u5c55\u793a\u6700\u65b0\u81e8\u5e8a\u9032\u5c55\uff0c\u518d\u4e00\u6b21\u9ad4\u73fe\u4e86\u570b\u969b\u8840\u6db2\u5b78\u754c\u5c0d\u8010\u7acb\u514b\u00ae\u7684\u5de8\u5927\u8a8d\u53ef\u3002\u76ee\u524d\uff0c\u8a72\u54c1\u7a2e\u67093\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u3002\u6b64\u5916\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u91cd\u9ede\u54c1\u7a2e\u6709\u591a\u9805\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5145\u5206\u986f\u73fe\u4e86\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u548c\u958b\u767c\u5be6\u529b\u3002\u6211\u5011\u671f\u5f85\u5728\u5f8c\u7e8c\u6703\u8b70\u671f\u9593\u8207\u5927\u5bb6\u5206\u4eab\u76f8\u95dc\u7814\u7a76\u7684\u8a73\u5be6\u6578\u64da\u3002\u672a\u4f86\uff0c\u4e9e\u76db\u91ab\u85e5\u5c07\u9032\u4e00\u6b65\u52a0\u901f\u63a8\u9032\u81e8\u5e8a\u958b\u767c\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d ASH 2025\u4e9e\u76db\u91ab\u85e5\u7522\u54c1\u76f8\u95dc\u7814\u7a76\u4e00\u89bd\uff1a \u5c55\u793a\u5f62\u5f0f \u54c1\u7a2e \u6458\u8981\u6a19\u984c \u7de8\u865f \u53e3\u982d\u5831\u544a \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis) \u4e00\u9805\u95dc\u65bc\u5229\u6c99\u6258\u514b\u62c9\u55ae\u85e5\u6cbb\u7642\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08BTKi\uff09\u6cbb\u7642\u5931\u6557\u7684\u5fa9\u767c\/\u96e3\u6cbb\u6027\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/ \u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u6ce8\u518a\u6027II\u671f\u7814\u7a76\u7d50\u679c 88 \u58c1\u5831\u5c55\u793a \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 Results of the APG2575AU101 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax\u2013exposed myeloid malignancies \u5229\u6c99\u6258\u514b\u62c9\u806f\u5408\u963f\u624e\u80de\u7518\u6cbb\u7642\u521d\u6cbb\u6216\u65e2\u5f80\u4f7f\u7528\u904e\u7dad\u5948\u6258\u514b\u7684\u9ad3\u7cfb\u816b\u7624\u7684\u81e8\u5e8a\u7814\u7a76\uff08APG2575AU101\uff09\u7d50\u679c 1641 \u5967\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Results of POLARIS-1, a global phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) \u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684 \u5168\u7403III\u671f\u7814\u7a76POLARIS-1\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c 1574 Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations \u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u60272\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08CML-CP\uff09\uff0c \u5305\u62ec\u7121T315I\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08BAT\uff09\uff1a4\u5e74\u96a8\u8a2a\u671f 3788 Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML) \u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u6578\u64da 3782 Preclinical and clinical Study of olverembatinib in patients with myeloid\/lymphoid neoplasms with FGFR1 rearrangement \u5967\u96f7\u5df4\u66ff\u5c3c\u7684\u81e8\u5e8a\u524d\u8207\u81e8\u5e8a\u7814\u7a76\uff1a\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\/\u6dcb\u5df4\u816b\u7624 1979 Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice report \u5967\u96f7\u5df4\u66ff\u5c3c\u4ecb\u5c0e\u7684\u6df1\u5ea6\u7de9\u89e3\u63d0\u5347\u7570\u57fa\u56e0\u5e72\u7d30\u80de\u79fb\u690d\u5728\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u6025\u8b8a\u671f\u60a3\u8005\u4e2d\u7684\u7642\u6548\uff1a \u9996\u4efd\u771f\u5be6\u4e16\u754c\u5be6\u8e10\u5831\u544a 1999 The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, control trial \u5c0d\u65bc\u65e2\u5f80\u63a5\u53d7\u904e\u81f3\u5c11\u5169\u7a2eTKI\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u6027\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\uff0c\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u8207\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a \u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u5c0d\u7167\u7814\u7a76 3779 Clinical and molecular features associated with glucolipid metabolic disorders and cardio-\/cerebro-vascular adverse events in CML patients receiving olverembatinib therapy \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u60a3\u8005\u51fa\u73fe\u7cd6\u8102\u4ee3\u8b1d\u7d0a\u4e82\u53ca\u5fc3\/\u8166\u8840\u7ba1\u4e0d\u826f\u4e8b\u4ef6\u7684 \u81e8\u5e8a\u8207\u5206\u5b50\u7279\u5f81 5561 APG-5918 Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs\/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM) \u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\uff08EED\uff09\u6291\u5236\u5291APG-5918\u55ae\u85e5\u5728\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d\u4e86\u514d\u75ab\u8abf\u7bc0\u85e5\u7269\uff08IMiD\uff09\u8010\u85e5\u6027\u4e26\u986f\u793a\u4e86 \u8207IMiDs\/Cereblon E3\u9023\u63a5\u9176\u8abf\u7bc0\u5291\uff08CELMoDs\uff09\u7684\u5354\u540c\u6548\u61c9 1528 \u5728\u7dda\u767c\u5e03 \u5967\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Single CAR-t infusion during front-line consolidation induces deep and sustained remissionin newly diagnosed adult ph+b- ALL: A prospective phase 2 study \u5c0d\u65bc\u65b0\u8a3a\u65b7\u7684\u6210\u4ebaPh\u967d\u6027B-ALL\u60a3\u8005\uff0c\u5728\u4e00\u7dda\u978f\u56fa\u6cbb\u7642\u968e\u6bb5\u9032\u884c\u55ae\u6b21CAR-T\u7d30\u80de\u8f38\u6ce8\uff0c\u53ef\u8a98\u5c0e\u6df1\u5ea6\u4e14\u6301\u4e45\u7684\u7de9\u89e3\uff1a\u4e00\u9805\u524d\u77bb\u6027II\u671f\u7814\u7a76\u3002 442 \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 BCL-2 inhibition in North American adult T-cell leukemia\/lymphoma: Preclinical insightsand early clinical outcomes BCL-2\u6291\u5236\u5291\u5728\u5317\u7f8e\u6210\u4ebaT\u7d30\u80de\u767d\u8840\u75c5\/\u6dcb\u5df4\u7624\u4e2d\u7684\u9776\u5411\u6cbb\u7642\uff1a\u81e8\u5e8a\u524d\u7814\u7a76\u8207\u65e9\u671f\u81e8\u5e8a\u7d50\u679c 3304 \u5967\u96f7\u5df4\u66ff\u5c3c\u5165\u90782025 ASH\u5e74\u6703\u7684\u4e3b\u8981\u7814\u7a76\u6458\u8981\u5982\u4e0b\uff1a\uff08\u5229\u6c99\u6258\u514b\u62c9\u5165\u9078ASH\u5e74\u6703\u7684\u6458\u8981\u8a73\u7d30\u4fe1\u606f\u53c3\u898b\u540c\u671f\u767c\u5e03\u7684\u53e6\u4e00\u7bc7\u65b0\u805e\u7a3f\uff09 Results of POLARIS-1, a global Phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)\u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684\u5168\u7403III\u671f\u7814\u7a76POLARIS-1\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a1574\u5206\u6703\u5834\uff1a613. \u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u540c\u7a2e\u79fb\u690d\u4ee5\u5916\u7684\u7642\u6cd5\uff1a\u58c1\u5831\u5c55\u793aI\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67086\u65e5\uff0c\u661f\u671f\u516d\uff0c\u4e0b\u534817:30 \u2013 19:30\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0a\u53486:30 \u2013 8:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388\u5831\u544a\u4eba\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388\u6838\u5fc3\u8981\u9ede\uff1a\u8a72\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff1bNCT06051409\uff09\u70ba\u4e00\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u5728\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff1b\u9006\u8f49\u9304qPCR\u65b9\u6cd5\u6aa2\u6e2cBCR-ABL1\/ABL1\u22640.01%\uff09\u9670\u6027\u7387\u3002 \u7642\u6548\u6578\u64da\uff1a \u622a\u81f32025\u5e747\u670818\u65e5\uff0c\u572853\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c50\u4f8b\u60a3\u8005\uff0894.3%\uff09\u5728\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5be6\u73fe\u4e86\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u6216CR\u4f34\u4e0d\u5b8c\u5168\u8840\u6db2\u5b78\u6062\u5fa9\uff0c\u6700\u4f73MRD\u9670\u6027\u7387\u548cMRD\u9670\u6027CR\u7387\u5206\u5225\u70ba66.0%\u548c64.2%\u3002 IKZF1plus\uff08\u5c24\u5176\u5408\u4e26BTG1\u7f3a\u5931\uff09\u662fB-ALL\u516c\u8a8d\u7684\u9ad8\u5371\u56e0\u7d20\uff0c\u5e38\u5c0e\u81f4\u5316\u7642\u8010\u85e5\u8207\u9ad8\u5fa9\u767c\u3002\u5728\u672c\u7814\u7a7610\u4f8b\u651c\u5e36\u6b64\u7279\u5f81\u7684\u60a3\u8005\u4e2d\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642\u7684\u5206\u5b50\u5b78\u7de9\u89e3\u7387\u9ad8\u905490%\uff089\/10\uff09\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5291\u91cf\u5316\u7642\u8010\u53d7\u6027\u826f\u597d\u3002\u5e38\u898b\u7684\uff08\u767c\u751f\u7387>15%\uff093\u7d1a\u6216\u4ee5\u4e0a\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u70ba\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\u75c7\uff0863.6%\uff09\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\uff0856.4%\uff09\u3001\u767d\u7d30\u80de\u6e1b\u5c11\u75c7\uff0854.5%\uff09\u3001\u8ca7\u8840\uff0849.1%\uff09\u3001\u80ba\u708e\uff0830.9%\uff09\u3001\u4f4e\u9240\u8840\u75c7\uff0820%\uff09\u548c\u809d\u529f\u80fd\u7570\u5e38\uff0816.4%\uff09\u3002 \u7d50\u8ad6\uff1a\u5728\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6cbb\u7642\u7684\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\uff0c\u81f3\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642MRD\u9670\u6027CR\u7387\u905464.2%\uff0c\u4e26\u986f\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u3002 Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations\u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u60272\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08CML-CP\uff09\uff0c\u5305\u62ec\u7121T315I\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08BAT\uff09\uff1a4\u5e74\u96a8\u8a2a\u671f\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a3788\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 \u2013 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e7412\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 \u2013 9:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388\u5831\u544a\u4eba\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388Highlights:\u6838\u5fc3\u8981\u9ede\uff1a \u8a72\u7814\u7a76\uff08NCT04126681\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u96a8\u6a5f\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7684\u95dc\u9375\u6ce8\u518aII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u672c\u5831\u544a\u70ba\u4e00\u98052023ASH\u5e74\u6703\u53e3\u982d\u5831\u544a\u7684\u7814\u7a76\u66f4\u65b0\u6578\u64da\u3002\u622a\u81f32025\u5e741\u670813\u65e5\uff0c\u5171\u6709144\u4f8bCML-CP\u60a3\u8005\u5165\u7d44\uff0c\u5176\u4e2d105\u4f8b\u70ba\u4e0d\u4f34T315I\u7a81\u8b8a\u60a3\u8005\u3002 \u5728\u672c\u7814\u7a76\u4e2d\uff0c\u60a3\u8005\u88ab\u6309\u71672:1 \u6bd4\u4f8b\u96a8\u6a5f\u5206\u7d44\u9032\u5165\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548c\u7814\u7a76\u8005\u6c7a\u5b9a\u7684\u73fe\u6709\u6700\u4f73\u6cbb\u7642\uff08BAT\uff09\u5c0d\u7167\u7d44\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u7121\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u3002 \u7642\u6548\u6578\u64da\uff1a \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u986f\u8457\u9577\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CMP-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba21.22\u500b\u6708\u548c2.86\u500b\u6708\uff08P < 0.001\uff09\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba11.96 \u548c3.14\u500b\u6708\uff08P = 0.0159\uff09\u3002 \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u5176\u4ed6\u7642\u6548\u6307\u6a19\u986f\u8457\u9ad8\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u5b8c\u5168\u8840\u6db2\u5b78\u7de9\u89e3(CHR)\u7387\u5206\u5225\u70ba85% \u548c34.8%\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u5206\u5225\u70ba37.5%\u548c18.9%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u5206\u5225\u70ba29.5%\u548c8.1%\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0cCHR\u5206\u5225\u70ba82.1% \u548c50.0%\uff0cCCyR\u5206\u5225\u70ba25.8%\u548c20.7%\uff0cMMR\u5206\u5225\u70ba16.1%\u548c 10.3%\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u5728\u4f34\u6216\u4e0d\u4f34T315I\u7a81\u8b8a\u7684CML-CP\u60a3\u8005\u4e2d\u5747\u5c55\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u6db2\u5b78\u6bd2\u6027\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6cbb\u7642\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u53d7\u8a66\u8005\uff0c\u5305\u62ec\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u6642\uff0c\u8f03BAT\u6cbb\u7642\u7d44\u5c55\u793a\u51fa\u660e\u986f\u6cbb\u7642\u512a\u52e2\u3002 Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML)\u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642CP-CML\u60a3\u8005\u6578\u64da\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a3782\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 - 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e74 12\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 - 9:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388\u5831\u544a\u4eba\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388\u6838\u5fc3\u8981\u9ede\uff1a\u8a72\u7814\u7a76\uff08ChiCTR2200061655\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u9694\u65e5\u53e3\u670d40mg\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u65e2\u5f80\u4f7f\u7528\u904e\u4e00\u7a2eTKI\u6cbb\u7642\u5f8c\u8010\u85e5\u6216\u4e0d\u8010\u53d7\uff08\u5305\u62ec\u4f0a\u99ac\u66ff\u5c3c\u3001\u6c1f\u99ac\u66ff\u5c3c\u3001\u5c3c\u6d1b\u66ff\u5c3c\u53ca\u9054\u6c99\u66ff\u5c3c\u7b49\uff09\u7684\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u622a\u81f32025\u5e747\u670824\u65e5\uff0c\u5171\u5165\u7d44\u975eT315I \u7a81\u8b8a\u7684CP-CML \u60a3\u800547\u4f8b\u3002 \u7642\u6548\u6578\u64da\uff1a \u622a\u81f32025\u5e747\u670824\u65e5\uff0c39\u4f8b\uff0883.0%\uff09\u60a3\u8005\u63a5\u53d7\u4e86\u81f3\u5c111\u6b21\u7642\u6548\u8a55\u4f30\uff0c36\u4f8b\uff0876.6%\uff09\u63a5\u53d7\u4e86\u81f3\u5c112\u6b21\u7642\u6548\u8a55\u4f30\uff0c34\u4f8b\uff0872.3%\uff09\u63a5\u53d7\u4e86\u81f3\u5c113\u6b21\u7642\u6548\u8a55\u4f30\u30022\u4f8b\u60a3\u8005\u5c1a\u672a\u9032\u884c\u9996\u6b21\u7642\u6548\u8a55\u4f30\u3002 \u81f3\u622a\u6b62\u65e5\u671f\uff0c71.8%\uff0828\/39\uff09\u7684\u60a3\u8005\u7372CCyR\uff0c43.6%\uff0817\/39\uff09\u7372MMR\u3002\u7b2c6\u30019\u300112\u300115\u300118\u300121\u300124\u500b\u5468\u671f\u8a55\u4f30\u7684CCyR\u7387\u548cMMR\u7387\u5206\u5225\u70ba54.3%\u548c25.7%\u300166.7%\u548c33.3%\u300174.2%\u548c35.5%\u300184.6%\u548c46.2%\u300185.7% \u548c 47.6%\u300190.0% \u548c 60.0%\u300189.5% \u548c 57.9%\u3002\u63d0\u793a\u7642\u6548\u96a8\u7528\u85e5\u6642\u9593\u5ef6\u9577\u800c\u7de9\u89e3\u9010\u6f38\u52a0\u6df1\u3002 \u572839\u4f8b\u7642\u6548\u53ef\u8a55\u4f30\u7684\u60a3\u8005\u4e2d\uff0c\u670930\u4f8b\u60a3\u8005\u65e2\u5f80\u4ee5\u4e8c\u4ee3TKI\u4f5c\u70ba\u4e00\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d76.7%\uff0823\/30\uff09\u7372\u5f97CCyR\uff0c43.3%\uff0813\/30\uff09\u7372\u5f97MMR\uff1b\u5728\u65e2\u5f80\u63a5\u53d7\u4f0a\u99ac\u66ff\u5c3c\u6cbb\u7642\u76849\u4f8b\u60a3\u8005\u4e2d\uff0c55.6%\uff085\/9\uff09\u7372\u5f97CCyR\uff0c44.4%\uff084\/9\uff09\u7372\u5f97MMR\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u4e2d\u4f4d\uff08\u5340\u9593\uff09\u6cbb\u7642\u6642\u959316.0\uff081-18\uff09\u500b\u6708\u3002\u5171\u670942\u4f8b\uff0889.4%\uff09\u60a3\u8005\u767c\u751f\u4e86\u4efb\u4f55\u7d1a\u5225\u7684\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u4e8b\u4ef6\uff08TRAEs\uff09\uff0c\u5176\u4e2d21\u4f8b\uff0844.7%\uff09\u767c\u751f\u4e86\u22653\u7d1aTRAEs\uff0c6\u4f8b\uff0812.8%\uff09\u767c\u751f\u4e86\u8207\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dc\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\uff08SAEs\uff09\u3002\u22653\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u53cd\u61c9\u5305\u62ec\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.6%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0825.5%\uff09\u548c\u8ca7\u8840\uff088.5%\uff09\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dcSAEs\u5305\u62ec\u8840\u5c0f\u677f\u8a08\u6578\u6e1b\u5c11\uff086.4%\uff09\u3001\u8ca7\u8840\u3001\u9aa8\u9ad3\u6291\u5236\u548c\u767c\u71b1\uff08\u54042.1%\uff09\u3002\u7121\u6b7b\u4ea1\u5831\u544a\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u80fd\u70ba\u4e8c\u7ddaCP-CML\u60a3\u8005\u63d0\u4f9b\u4e00\u7a2e\u5b89\u5168\u6709\u6548\u7684\u6cbb\u7642\u9078\u64c7\uff0c\u5c24\u5176\u662f\u5c0d\u65bc\u4e00\u7dda\u4f7f\u7528\u4e8c\u4ee3\u00a0TKIs\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\u3002 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c\u00a0MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u65e2\u5f80\u7d93\u904e\u81f3\u5c11\u5305\u542b\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u4e00\u7a2e\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u3001\u6b50\u6d32EMA\u8207\u4e2d\u570bCDE\u540c\u6b65\u6279\u51c6\u958b\u5c55\u7684\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff09\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u7cfb\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pingtungtimes.com.tw\/?p=378515\" \/>\n<meta property=\"og:locale\" content=\"zh_TW\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u30102025 ASH\u3011\u4e9e\u76db\u91ab\u85e5\u8010\u7acb\u514b\u00ae\u591a\u9805\u7814\u7a76\u5165\u9078\uff0cPOLARIS-1\u7814\u7a76\u6578\u64da\u9996\u6b21\u767c\u5e03 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"og:description\" content=\"\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2025\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ --\u00a0\u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u6709\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c8\u5e74\u5165\u9078ASH\u5e74\u6703\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u00ae\u3001\u5229\u751f\u59a5\u00ae\u3001APG-5918\uff09\u6709\u591a\u9805\u81e8\u5e8a\u548c\u81e8\u5e8a\u524d\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5176\u4e2d\u4e00\u9805\u7372\u53e3\u982d\u5831\u544a\u3002 \u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u3002\u5176\u5728\u4e2d\u570b\u7684\u5546\u696d\u5316\u63a8\u5ee3\u7531\u4e9e\u76db\u91ab\u85e5\u548c\u4fe1\u9054\u751f\u7269\u5171\u540c\u8ca0\u8cac\u3002\u516c\u53f8\u5c07\u5728\u6b64\u6b21ASH\u5e74\u6703\u4e0a\uff0c\u9996\u6b21\u767c\u5e03\u8010\u7acb\u514b\u00ae\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684\u5168\u7403III\u671f\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff09\u6700\u65b0\u6578\u64da\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5CML-CP\u60a3\u8005\u7684\u96a8\u6a5f\u5c0d\u7167\u6ce8\u518aII\u671f\u7814\u7a76\u76844\u5e74\u96a8\u8a2a\u6578\u64da\u3001\u548c\u5176\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCML-CP\u60a3\u8005\u7684\u6578\u64da\u4e5f\u5c07\u5728\u6b64\u6b21\u6703\u8b70\u4e0a\u66f4\u65b0\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u6703\u662f\u5168\u7403\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u5b78\u8853\u76db\u6703\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u84cb\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7642\u7814\u7a76\u3002\u7b2c67\u5c46ASH\u5e74\u6703\u5c07\u65bc\u7576\u5730\u6642\u95932025\u5e7412\u67086\u65e5\u81f39\u65e5\u9593\u5728\u7f8e\u570b\u4f5b\u7f85\u88e1\u9054\u5dde\u5967\u862d\u591a\u5e02\u4ee5\u7dda\u4e0b\u7d50\u5408\u7dda\u4e0a\u7684\u5f62\u5f0f\u8209\u884c\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u4eca\u5e74\u5c07\u662f\u8010\u7acb\u514b\u00ae\u9023\u7e8c\u7b2c8\u5e74\u5728ASH\u5e74\u6703\u4e0a\u5c55\u793a\u6700\u65b0\u81e8\u5e8a\u9032\u5c55\uff0c\u518d\u4e00\u6b21\u9ad4\u73fe\u4e86\u570b\u969b\u8840\u6db2\u5b78\u754c\u5c0d\u8010\u7acb\u514b\u00ae\u7684\u5de8\u5927\u8a8d\u53ef\u3002\u76ee\u524d\uff0c\u8a72\u54c1\u7a2e\u67093\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u3002\u6b64\u5916\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u91cd\u9ede\u54c1\u7a2e\u6709\u591a\u9805\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5145\u5206\u986f\u73fe\u4e86\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u548c\u958b\u767c\u5be6\u529b\u3002\u6211\u5011\u671f\u5f85\u5728\u5f8c\u7e8c\u6703\u8b70\u671f\u9593\u8207\u5927\u5bb6\u5206\u4eab\u76f8\u95dc\u7814\u7a76\u7684\u8a73\u5be6\u6578\u64da\u3002\u672a\u4f86\uff0c\u4e9e\u76db\u91ab\u85e5\u5c07\u9032\u4e00\u6b65\u52a0\u901f\u63a8\u9032\u81e8\u5e8a\u958b\u767c\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d ASH 2025\u4e9e\u76db\u91ab\u85e5\u7522\u54c1\u76f8\u95dc\u7814\u7a76\u4e00\u89bd\uff1a \u5c55\u793a\u5f62\u5f0f \u54c1\u7a2e \u6458\u8981\u6a19\u984c \u7de8\u865f \u53e3\u982d\u5831\u544a \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis) \u4e00\u9805\u95dc\u65bc\u5229\u6c99\u6258\u514b\u62c9\u55ae\u85e5\u6cbb\u7642\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08BTKi\uff09\u6cbb\u7642\u5931\u6557\u7684\u5fa9\u767c\/\u96e3\u6cbb\u6027\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/ \u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u6ce8\u518a\u6027II\u671f\u7814\u7a76\u7d50\u679c 88 \u58c1\u5831\u5c55\u793a \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 Results of the APG2575AU101 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax\u2013exposed myeloid malignancies \u5229\u6c99\u6258\u514b\u62c9\u806f\u5408\u963f\u624e\u80de\u7518\u6cbb\u7642\u521d\u6cbb\u6216\u65e2\u5f80\u4f7f\u7528\u904e\u7dad\u5948\u6258\u514b\u7684\u9ad3\u7cfb\u816b\u7624\u7684\u81e8\u5e8a\u7814\u7a76\uff08APG2575AU101\uff09\u7d50\u679c 1641 \u5967\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Results of POLARIS-1, a global phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) \u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684 \u5168\u7403III\u671f\u7814\u7a76POLARIS-1\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c 1574 Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations \u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u60272\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08CML-CP\uff09\uff0c \u5305\u62ec\u7121T315I\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08BAT\uff09\uff1a4\u5e74\u96a8\u8a2a\u671f 3788 Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML) \u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u6578\u64da 3782 Preclinical and clinical Study of olverembatinib in patients with myeloid\/lymphoid neoplasms with FGFR1 rearrangement \u5967\u96f7\u5df4\u66ff\u5c3c\u7684\u81e8\u5e8a\u524d\u8207\u81e8\u5e8a\u7814\u7a76\uff1a\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\/\u6dcb\u5df4\u816b\u7624 1979 Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice report \u5967\u96f7\u5df4\u66ff\u5c3c\u4ecb\u5c0e\u7684\u6df1\u5ea6\u7de9\u89e3\u63d0\u5347\u7570\u57fa\u56e0\u5e72\u7d30\u80de\u79fb\u690d\u5728\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u6025\u8b8a\u671f\u60a3\u8005\u4e2d\u7684\u7642\u6548\uff1a \u9996\u4efd\u771f\u5be6\u4e16\u754c\u5be6\u8e10\u5831\u544a 1999 The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, control trial \u5c0d\u65bc\u65e2\u5f80\u63a5\u53d7\u904e\u81f3\u5c11\u5169\u7a2eTKI\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u6027\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\uff0c\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u8207\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a \u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u5c0d\u7167\u7814\u7a76 3779 Clinical and molecular features associated with glucolipid metabolic disorders and cardio-\/cerebro-vascular adverse events in CML patients receiving olverembatinib therapy \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u60a3\u8005\u51fa\u73fe\u7cd6\u8102\u4ee3\u8b1d\u7d0a\u4e82\u53ca\u5fc3\/\u8166\u8840\u7ba1\u4e0d\u826f\u4e8b\u4ef6\u7684 \u81e8\u5e8a\u8207\u5206\u5b50\u7279\u5f81 5561 APG-5918 Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs\/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM) \u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\uff08EED\uff09\u6291\u5236\u5291APG-5918\u55ae\u85e5\u5728\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d\u4e86\u514d\u75ab\u8abf\u7bc0\u85e5\u7269\uff08IMiD\uff09\u8010\u85e5\u6027\u4e26\u986f\u793a\u4e86 \u8207IMiDs\/Cereblon E3\u9023\u63a5\u9176\u8abf\u7bc0\u5291\uff08CELMoDs\uff09\u7684\u5354\u540c\u6548\u61c9 1528 \u5728\u7dda\u767c\u5e03 \u5967\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Single CAR-t infusion during front-line consolidation induces deep and sustained remissionin newly diagnosed adult ph+b- ALL: A prospective phase 2 study \u5c0d\u65bc\u65b0\u8a3a\u65b7\u7684\u6210\u4ebaPh\u967d\u6027B-ALL\u60a3\u8005\uff0c\u5728\u4e00\u7dda\u978f\u56fa\u6cbb\u7642\u968e\u6bb5\u9032\u884c\u55ae\u6b21CAR-T\u7d30\u80de\u8f38\u6ce8\uff0c\u53ef\u8a98\u5c0e\u6df1\u5ea6\u4e14\u6301\u4e45\u7684\u7de9\u89e3\uff1a\u4e00\u9805\u524d\u77bb\u6027II\u671f\u7814\u7a76\u3002 442 \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 BCL-2 inhibition in North American adult T-cell leukemia\/lymphoma: Preclinical insightsand early clinical outcomes BCL-2\u6291\u5236\u5291\u5728\u5317\u7f8e\u6210\u4ebaT\u7d30\u80de\u767d\u8840\u75c5\/\u6dcb\u5df4\u7624\u4e2d\u7684\u9776\u5411\u6cbb\u7642\uff1a\u81e8\u5e8a\u524d\u7814\u7a76\u8207\u65e9\u671f\u81e8\u5e8a\u7d50\u679c 3304 \u5967\u96f7\u5df4\u66ff\u5c3c\u5165\u90782025 ASH\u5e74\u6703\u7684\u4e3b\u8981\u7814\u7a76\u6458\u8981\u5982\u4e0b\uff1a\uff08\u5229\u6c99\u6258\u514b\u62c9\u5165\u9078ASH\u5e74\u6703\u7684\u6458\u8981\u8a73\u7d30\u4fe1\u606f\u53c3\u898b\u540c\u671f\u767c\u5e03\u7684\u53e6\u4e00\u7bc7\u65b0\u805e\u7a3f\uff09 Results of POLARIS-1, a global Phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)\u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684\u5168\u7403III\u671f\u7814\u7a76POLARIS-1\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a1574\u5206\u6703\u5834\uff1a613. \u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u540c\u7a2e\u79fb\u690d\u4ee5\u5916\u7684\u7642\u6cd5\uff1a\u58c1\u5831\u5c55\u793aI\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67086\u65e5\uff0c\u661f\u671f\u516d\uff0c\u4e0b\u534817:30 \u2013 19:30\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0a\u53486:30 \u2013 8:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388\u5831\u544a\u4eba\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388\u6838\u5fc3\u8981\u9ede\uff1a\u8a72\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff1bNCT06051409\uff09\u70ba\u4e00\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u5728\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff1b\u9006\u8f49\u9304qPCR\u65b9\u6cd5\u6aa2\u6e2cBCR-ABL1\/ABL1\u22640.01%\uff09\u9670\u6027\u7387\u3002 \u7642\u6548\u6578\u64da\uff1a \u622a\u81f32025\u5e747\u670818\u65e5\uff0c\u572853\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c50\u4f8b\u60a3\u8005\uff0894.3%\uff09\u5728\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5be6\u73fe\u4e86\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u6216CR\u4f34\u4e0d\u5b8c\u5168\u8840\u6db2\u5b78\u6062\u5fa9\uff0c\u6700\u4f73MRD\u9670\u6027\u7387\u548cMRD\u9670\u6027CR\u7387\u5206\u5225\u70ba66.0%\u548c64.2%\u3002 IKZF1plus\uff08\u5c24\u5176\u5408\u4e26BTG1\u7f3a\u5931\uff09\u662fB-ALL\u516c\u8a8d\u7684\u9ad8\u5371\u56e0\u7d20\uff0c\u5e38\u5c0e\u81f4\u5316\u7642\u8010\u85e5\u8207\u9ad8\u5fa9\u767c\u3002\u5728\u672c\u7814\u7a7610\u4f8b\u651c\u5e36\u6b64\u7279\u5f81\u7684\u60a3\u8005\u4e2d\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642\u7684\u5206\u5b50\u5b78\u7de9\u89e3\u7387\u9ad8\u905490%\uff089\/10\uff09\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5291\u91cf\u5316\u7642\u8010\u53d7\u6027\u826f\u597d\u3002\u5e38\u898b\u7684\uff08\u767c\u751f\u7387>15%\uff093\u7d1a\u6216\u4ee5\u4e0a\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u70ba\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\u75c7\uff0863.6%\uff09\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\uff0856.4%\uff09\u3001\u767d\u7d30\u80de\u6e1b\u5c11\u75c7\uff0854.5%\uff09\u3001\u8ca7\u8840\uff0849.1%\uff09\u3001\u80ba\u708e\uff0830.9%\uff09\u3001\u4f4e\u9240\u8840\u75c7\uff0820%\uff09\u548c\u809d\u529f\u80fd\u7570\u5e38\uff0816.4%\uff09\u3002 \u7d50\u8ad6\uff1a\u5728\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6cbb\u7642\u7684\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\uff0c\u81f3\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642MRD\u9670\u6027CR\u7387\u905464.2%\uff0c\u4e26\u986f\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u3002 Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations\u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u60272\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08CML-CP\uff09\uff0c\u5305\u62ec\u7121T315I\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08BAT\uff09\uff1a4\u5e74\u96a8\u8a2a\u671f\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a3788\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 \u2013 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e7412\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 \u2013 9:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388\u5831\u544a\u4eba\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388Highlights:\u6838\u5fc3\u8981\u9ede\uff1a \u8a72\u7814\u7a76\uff08NCT04126681\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u96a8\u6a5f\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7684\u95dc\u9375\u6ce8\u518aII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u672c\u5831\u544a\u70ba\u4e00\u98052023ASH\u5e74\u6703\u53e3\u982d\u5831\u544a\u7684\u7814\u7a76\u66f4\u65b0\u6578\u64da\u3002\u622a\u81f32025\u5e741\u670813\u65e5\uff0c\u5171\u6709144\u4f8bCML-CP\u60a3\u8005\u5165\u7d44\uff0c\u5176\u4e2d105\u4f8b\u70ba\u4e0d\u4f34T315I\u7a81\u8b8a\u60a3\u8005\u3002 \u5728\u672c\u7814\u7a76\u4e2d\uff0c\u60a3\u8005\u88ab\u6309\u71672:1 \u6bd4\u4f8b\u96a8\u6a5f\u5206\u7d44\u9032\u5165\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548c\u7814\u7a76\u8005\u6c7a\u5b9a\u7684\u73fe\u6709\u6700\u4f73\u6cbb\u7642\uff08BAT\uff09\u5c0d\u7167\u7d44\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u7121\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u3002 \u7642\u6548\u6578\u64da\uff1a \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u986f\u8457\u9577\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CMP-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba21.22\u500b\u6708\u548c2.86\u500b\u6708\uff08P < 0.001\uff09\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba11.96 \u548c3.14\u500b\u6708\uff08P = 0.0159\uff09\u3002 \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u5176\u4ed6\u7642\u6548\u6307\u6a19\u986f\u8457\u9ad8\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u5b8c\u5168\u8840\u6db2\u5b78\u7de9\u89e3(CHR)\u7387\u5206\u5225\u70ba85% \u548c34.8%\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u5206\u5225\u70ba37.5%\u548c18.9%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u5206\u5225\u70ba29.5%\u548c8.1%\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0cCHR\u5206\u5225\u70ba82.1% \u548c50.0%\uff0cCCyR\u5206\u5225\u70ba25.8%\u548c20.7%\uff0cMMR\u5206\u5225\u70ba16.1%\u548c 10.3%\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u5728\u4f34\u6216\u4e0d\u4f34T315I\u7a81\u8b8a\u7684CML-CP\u60a3\u8005\u4e2d\u5747\u5c55\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u6db2\u5b78\u6bd2\u6027\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6cbb\u7642\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u53d7\u8a66\u8005\uff0c\u5305\u62ec\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u6642\uff0c\u8f03BAT\u6cbb\u7642\u7d44\u5c55\u793a\u51fa\u660e\u986f\u6cbb\u7642\u512a\u52e2\u3002 Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML)\u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642CP-CML\u60a3\u8005\u6578\u64da\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a3782\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 - 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e74 12\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 - 9:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388\u5831\u544a\u4eba\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388\u6838\u5fc3\u8981\u9ede\uff1a\u8a72\u7814\u7a76\uff08ChiCTR2200061655\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u9694\u65e5\u53e3\u670d40mg\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u65e2\u5f80\u4f7f\u7528\u904e\u4e00\u7a2eTKI\u6cbb\u7642\u5f8c\u8010\u85e5\u6216\u4e0d\u8010\u53d7\uff08\u5305\u62ec\u4f0a\u99ac\u66ff\u5c3c\u3001\u6c1f\u99ac\u66ff\u5c3c\u3001\u5c3c\u6d1b\u66ff\u5c3c\u53ca\u9054\u6c99\u66ff\u5c3c\u7b49\uff09\u7684\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u622a\u81f32025\u5e747\u670824\u65e5\uff0c\u5171\u5165\u7d44\u975eT315I \u7a81\u8b8a\u7684CP-CML \u60a3\u800547\u4f8b\u3002 \u7642\u6548\u6578\u64da\uff1a \u622a\u81f32025\u5e747\u670824\u65e5\uff0c39\u4f8b\uff0883.0%\uff09\u60a3\u8005\u63a5\u53d7\u4e86\u81f3\u5c111\u6b21\u7642\u6548\u8a55\u4f30\uff0c36\u4f8b\uff0876.6%\uff09\u63a5\u53d7\u4e86\u81f3\u5c112\u6b21\u7642\u6548\u8a55\u4f30\uff0c34\u4f8b\uff0872.3%\uff09\u63a5\u53d7\u4e86\u81f3\u5c113\u6b21\u7642\u6548\u8a55\u4f30\u30022\u4f8b\u60a3\u8005\u5c1a\u672a\u9032\u884c\u9996\u6b21\u7642\u6548\u8a55\u4f30\u3002 \u81f3\u622a\u6b62\u65e5\u671f\uff0c71.8%\uff0828\/39\uff09\u7684\u60a3\u8005\u7372CCyR\uff0c43.6%\uff0817\/39\uff09\u7372MMR\u3002\u7b2c6\u30019\u300112\u300115\u300118\u300121\u300124\u500b\u5468\u671f\u8a55\u4f30\u7684CCyR\u7387\u548cMMR\u7387\u5206\u5225\u70ba54.3%\u548c25.7%\u300166.7%\u548c33.3%\u300174.2%\u548c35.5%\u300184.6%\u548c46.2%\u300185.7% \u548c 47.6%\u300190.0% \u548c 60.0%\u300189.5% \u548c 57.9%\u3002\u63d0\u793a\u7642\u6548\u96a8\u7528\u85e5\u6642\u9593\u5ef6\u9577\u800c\u7de9\u89e3\u9010\u6f38\u52a0\u6df1\u3002 \u572839\u4f8b\u7642\u6548\u53ef\u8a55\u4f30\u7684\u60a3\u8005\u4e2d\uff0c\u670930\u4f8b\u60a3\u8005\u65e2\u5f80\u4ee5\u4e8c\u4ee3TKI\u4f5c\u70ba\u4e00\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d76.7%\uff0823\/30\uff09\u7372\u5f97CCyR\uff0c43.3%\uff0813\/30\uff09\u7372\u5f97MMR\uff1b\u5728\u65e2\u5f80\u63a5\u53d7\u4f0a\u99ac\u66ff\u5c3c\u6cbb\u7642\u76849\u4f8b\u60a3\u8005\u4e2d\uff0c55.6%\uff085\/9\uff09\u7372\u5f97CCyR\uff0c44.4%\uff084\/9\uff09\u7372\u5f97MMR\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u4e2d\u4f4d\uff08\u5340\u9593\uff09\u6cbb\u7642\u6642\u959316.0\uff081-18\uff09\u500b\u6708\u3002\u5171\u670942\u4f8b\uff0889.4%\uff09\u60a3\u8005\u767c\u751f\u4e86\u4efb\u4f55\u7d1a\u5225\u7684\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u4e8b\u4ef6\uff08TRAEs\uff09\uff0c\u5176\u4e2d21\u4f8b\uff0844.7%\uff09\u767c\u751f\u4e86\u22653\u7d1aTRAEs\uff0c6\u4f8b\uff0812.8%\uff09\u767c\u751f\u4e86\u8207\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dc\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\uff08SAEs\uff09\u3002\u22653\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u53cd\u61c9\u5305\u62ec\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.6%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0825.5%\uff09\u548c\u8ca7\u8840\uff088.5%\uff09\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dcSAEs\u5305\u62ec\u8840\u5c0f\u677f\u8a08\u6578\u6e1b\u5c11\uff086.4%\uff09\u3001\u8ca7\u8840\u3001\u9aa8\u9ad3\u6291\u5236\u548c\u767c\u71b1\uff08\u54042.1%\uff09\u3002\u7121\u6b7b\u4ea1\u5831\u544a\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u80fd\u70ba\u4e8c\u7ddaCP-CML\u60a3\u8005\u63d0\u4f9b\u4e00\u7a2e\u5b89\u5168\u6709\u6548\u7684\u6cbb\u7642\u9078\u64c7\uff0c\u5c24\u5176\u662f\u5c0d\u65bc\u4e00\u7dda\u4f7f\u7528\u4e8c\u4ee3\u00a0TKIs\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\u3002 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c\u00a0MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u65e2\u5f80\u7d93\u904e\u81f3\u5c11\u5305\u542b\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u4e00\u7a2e\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u3001\u6b50\u6d32EMA\u8207\u4e2d\u570bCDE\u540c\u6b65\u6279\u51c6\u958b\u5c55\u7684\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff09\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u7cfb\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pingtungtimes.com.tw\/?p=378515\" \/>\n<meta property=\"og:site_name\" content=\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pingtungnews\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T01:22:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1706\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u7f8e\u901a\u793e\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u4f5c\u8005:\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u7f8e\u901a\u793e\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u9810\u4f30\u95b1\u8b80\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 \u5206\u9418\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378515#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378515\"},\"author\":{\"name\":\"\u7f8e\u901a\u793e\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\"},\"headline\":\"\u30102025 ASH\u3011\u4e9e\u76db\u91ab\u85e5\u8010\u7acb\u514b\u00ae\u591a\u9805\u7814\u7a76\u5165\u9078\uff0cPOLARIS-1\u7814\u7a76\u6578\u64da\u9996\u6b21\u767c\u5e03\",\"datePublished\":\"2025-11-04T01:22:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378515\"},\"wordCount\":613,\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378515#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/Ascentage_APAC_Logo-12.jpg\",\"articleSection\":[\"\u7f8e\u901a\u793e\"],\"inLanguage\":\"zh-TW\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378515\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378515\",\"name\":\"\u30102025 ASH\u3011\u4e9e\u76db\u91ab\u85e5\u8010\u7acb\u514b\u00ae\u591a\u9805\u7814\u7a76\u5165\u9078\uff0cPOLARIS-1\u7814\u7a76\u6578\u64da\u9996\u6b21\u767c\u5e03 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378515#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378515#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/Ascentage_APAC_Logo-12.jpg\",\"datePublished\":\"2025-11-04T01:22:00+00:00\",\"description\":\"\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2025\u5e7411\u67084\u65e5 \\\/\u7f8e\u901a\u793e\\\/ --\u00a0\u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u6709\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c8\u5e74\u5165\u9078ASH\u5e74\u6703\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u00ae\u3001\u5229\u751f\u59a5\u00ae\u3001APG-5918\uff09\u6709\u591a\u9805\u81e8\u5e8a\u548c\u81e8\u5e8a\u524d\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5176\u4e2d\u4e00\u9805\u7372\u53e3\u982d\u5831\u544a\u3002 \u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u3002\u5176\u5728\u4e2d\u570b\u7684\u5546\u696d\u5316\u63a8\u5ee3\u7531\u4e9e\u76db\u91ab\u85e5\u548c\u4fe1\u9054\u751f\u7269\u5171\u540c\u8ca0\u8cac\u3002\u516c\u53f8\u5c07\u5728\u6b64\u6b21ASH\u5e74\u6703\u4e0a\uff0c\u9996\u6b21\u767c\u5e03\u8010\u7acb\u514b\u00ae\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684\u5168\u7403III\u671f\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff09\u6700\u65b0\u6578\u64da\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5CML-CP\u60a3\u8005\u7684\u96a8\u6a5f\u5c0d\u7167\u6ce8\u518aII\u671f\u7814\u7a76\u76844\u5e74\u96a8\u8a2a\u6578\u64da\u3001\u548c\u5176\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCML-CP\u60a3\u8005\u7684\u6578\u64da\u4e5f\u5c07\u5728\u6b64\u6b21\u6703\u8b70\u4e0a\u66f4\u65b0\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u6703\u662f\u5168\u7403\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u5b78\u8853\u76db\u6703\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u84cb\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7642\u7814\u7a76\u3002\u7b2c67\u5c46ASH\u5e74\u6703\u5c07\u65bc\u7576\u5730\u6642\u95932025\u5e7412\u67086\u65e5\u81f39\u65e5\u9593\u5728\u7f8e\u570b\u4f5b\u7f85\u88e1\u9054\u5dde\u5967\u862d\u591a\u5e02\u4ee5\u7dda\u4e0b\u7d50\u5408\u7dda\u4e0a\u7684\u5f62\u5f0f\u8209\u884c\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u4eca\u5e74\u5c07\u662f\u8010\u7acb\u514b\u00ae\u9023\u7e8c\u7b2c8\u5e74\u5728ASH\u5e74\u6703\u4e0a\u5c55\u793a\u6700\u65b0\u81e8\u5e8a\u9032\u5c55\uff0c\u518d\u4e00\u6b21\u9ad4\u73fe\u4e86\u570b\u969b\u8840\u6db2\u5b78\u754c\u5c0d\u8010\u7acb\u514b\u00ae\u7684\u5de8\u5927\u8a8d\u53ef\u3002\u76ee\u524d\uff0c\u8a72\u54c1\u7a2e\u67093\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u3002\u6b64\u5916\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u91cd\u9ede\u54c1\u7a2e\u6709\u591a\u9805\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5145\u5206\u986f\u73fe\u4e86\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u548c\u958b\u767c\u5be6\u529b\u3002\u6211\u5011\u671f\u5f85\u5728\u5f8c\u7e8c\u6703\u8b70\u671f\u9593\u8207\u5927\u5bb6\u5206\u4eab\u76f8\u95dc\u7814\u7a76\u7684\u8a73\u5be6\u6578\u64da\u3002\u672a\u4f86\uff0c\u4e9e\u76db\u91ab\u85e5\u5c07\u9032\u4e00\u6b65\u52a0\u901f\u63a8\u9032\u81e8\u5e8a\u958b\u767c\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d ASH 2025\u4e9e\u76db\u91ab\u85e5\u7522\u54c1\u76f8\u95dc\u7814\u7a76\u4e00\u89bd\uff1a \u5c55\u793a\u5f62\u5f0f \u54c1\u7a2e \u6458\u8981\u6a19\u984c \u7de8\u865f \u53e3\u982d\u5831\u544a \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed\\\/refractory chronic lymphocytic leukemia\\\/small lymphocytic lymphoma (CLL\\\/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis) \u4e00\u9805\u95dc\u65bc\u5229\u6c99\u6258\u514b\u62c9\u55ae\u85e5\u6cbb\u7642\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08BTKi\uff09\u6cbb\u7642\u5931\u6557\u7684\u5fa9\u767c\\\/\u96e3\u6cbb\u6027\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\\\/ \u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\\\/SLL\uff09\u60a3\u8005\u7684\u6ce8\u518a\u6027II\u671f\u7814\u7a76\u7d50\u679c 88 \u58c1\u5831\u5c55\u793a \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 Results of the APG2575AU101 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax\u2013exposed myeloid malignancies \u5229\u6c99\u6258\u514b\u62c9\u806f\u5408\u963f\u624e\u80de\u7518\u6cbb\u7642\u521d\u6cbb\u6216\u65e2\u5f80\u4f7f\u7528\u904e\u7dad\u5948\u6258\u514b\u7684\u9ad3\u7cfb\u816b\u7624\u7684\u81e8\u5e8a\u7814\u7a76\uff08APG2575AU101\uff09\u7d50\u679c 1641 \u5967\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Results of POLARIS-1, a global phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) \u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684 \u5168\u7403III\u671f\u7814\u7a76POLARIS-1\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c 1574 Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations \u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u60272\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08CML-CP\uff09\uff0c \u5305\u62ec\u7121T315I\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08BAT\uff09\uff1a4\u5e74\u96a8\u8a2a\u671f 3788 Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML) \u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u6578\u64da 3782 Preclinical and clinical Study of olverembatinib in patients with myeloid\\\/lymphoid neoplasms with FGFR1 rearrangement \u5967\u96f7\u5df4\u66ff\u5c3c\u7684\u81e8\u5e8a\u524d\u8207\u81e8\u5e8a\u7814\u7a76\uff1a\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\\\/\u6dcb\u5df4\u816b\u7624 1979 Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice report \u5967\u96f7\u5df4\u66ff\u5c3c\u4ecb\u5c0e\u7684\u6df1\u5ea6\u7de9\u89e3\u63d0\u5347\u7570\u57fa\u56e0\u5e72\u7d30\u80de\u79fb\u690d\u5728\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u6025\u8b8a\u671f\u60a3\u8005\u4e2d\u7684\u7642\u6548\uff1a \u9996\u4efd\u771f\u5be6\u4e16\u754c\u5be6\u8e10\u5831\u544a 1999 The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, control trial \u5c0d\u65bc\u65e2\u5f80\u63a5\u53d7\u904e\u81f3\u5c11\u5169\u7a2eTKI\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u6027\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\uff0c\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u8207\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a \u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u5c0d\u7167\u7814\u7a76 3779 Clinical and molecular features associated with glucolipid metabolic disorders and cardio-\\\/cerebro-vascular adverse events in CML patients receiving olverembatinib therapy \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u60a3\u8005\u51fa\u73fe\u7cd6\u8102\u4ee3\u8b1d\u7d0a\u4e82\u53ca\u5fc3\\\/\u8166\u8840\u7ba1\u4e0d\u826f\u4e8b\u4ef6\u7684 \u81e8\u5e8a\u8207\u5206\u5b50\u7279\u5f81 5561 APG-5918 Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs\\\/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM) \u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\uff08EED\uff09\u6291\u5236\u5291APG-5918\u55ae\u85e5\u5728\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d\u4e86\u514d\u75ab\u8abf\u7bc0\u85e5\u7269\uff08IMiD\uff09\u8010\u85e5\u6027\u4e26\u986f\u793a\u4e86 \u8207IMiDs\\\/Cereblon E3\u9023\u63a5\u9176\u8abf\u7bc0\u5291\uff08CELMoDs\uff09\u7684\u5354\u540c\u6548\u61c9 1528 \u5728\u7dda\u767c\u5e03 \u5967\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Single CAR-t infusion during front-line consolidation induces deep and sustained remissionin newly diagnosed adult ph+b- ALL: A prospective phase 2 study \u5c0d\u65bc\u65b0\u8a3a\u65b7\u7684\u6210\u4ebaPh\u967d\u6027B-ALL\u60a3\u8005\uff0c\u5728\u4e00\u7dda\u978f\u56fa\u6cbb\u7642\u968e\u6bb5\u9032\u884c\u55ae\u6b21CAR-T\u7d30\u80de\u8f38\u6ce8\uff0c\u53ef\u8a98\u5c0e\u6df1\u5ea6\u4e14\u6301\u4e45\u7684\u7de9\u89e3\uff1a\u4e00\u9805\u524d\u77bb\u6027II\u671f\u7814\u7a76\u3002 442 \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 BCL-2 inhibition in North American adult T-cell leukemia\\\/lymphoma: Preclinical insightsand early clinical outcomes BCL-2\u6291\u5236\u5291\u5728\u5317\u7f8e\u6210\u4ebaT\u7d30\u80de\u767d\u8840\u75c5\\\/\u6dcb\u5df4\u7624\u4e2d\u7684\u9776\u5411\u6cbb\u7642\uff1a\u81e8\u5e8a\u524d\u7814\u7a76\u8207\u65e9\u671f\u81e8\u5e8a\u7d50\u679c 3304 \u5967\u96f7\u5df4\u66ff\u5c3c\u5165\u90782025 ASH\u5e74\u6703\u7684\u4e3b\u8981\u7814\u7a76\u6458\u8981\u5982\u4e0b\uff1a\uff08\u5229\u6c99\u6258\u514b\u62c9\u5165\u9078ASH\u5e74\u6703\u7684\u6458\u8981\u8a73\u7d30\u4fe1\u606f\u53c3\u898b\u540c\u671f\u767c\u5e03\u7684\u53e6\u4e00\u7bc7\u65b0\u805e\u7a3f\uff09 Results of POLARIS-1, a global Phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)\u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684\u5168\u7403III\u671f\u7814\u7a76POLARIS-1\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a1574\u5206\u6703\u5834\uff1a613. \u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u540c\u7a2e\u79fb\u690d\u4ee5\u5916\u7684\u7642\u6cd5\uff1a\u58c1\u5831\u5c55\u793aI\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67086\u65e5\uff0c\u661f\u671f\u516d\uff0c\u4e0b\u534817:30 \u2013 19:30\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0a\u53486:30 \u2013 8:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388\u5831\u544a\u4eba\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388\u6838\u5fc3\u8981\u9ede\uff1a\u8a72\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff1bNCT06051409\uff09\u70ba\u4e00\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u5728\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff1b\u9006\u8f49\u9304qPCR\u65b9\u6cd5\u6aa2\u6e2cBCR-ABL1\\\/ABL1\u22640.01%\uff09\u9670\u6027\u7387\u3002 \u7642\u6548\u6578\u64da\uff1a \u622a\u81f32025\u5e747\u670818\u65e5\uff0c\u572853\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c50\u4f8b\u60a3\u8005\uff0894.3%\uff09\u5728\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5be6\u73fe\u4e86\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u6216CR\u4f34\u4e0d\u5b8c\u5168\u8840\u6db2\u5b78\u6062\u5fa9\uff0c\u6700\u4f73MRD\u9670\u6027\u7387\u548cMRD\u9670\u6027CR\u7387\u5206\u5225\u70ba66.0%\u548c64.2%\u3002 IKZF1plus\uff08\u5c24\u5176\u5408\u4e26BTG1\u7f3a\u5931\uff09\u662fB-ALL\u516c\u8a8d\u7684\u9ad8\u5371\u56e0\u7d20\uff0c\u5e38\u5c0e\u81f4\u5316\u7642\u8010\u85e5\u8207\u9ad8\u5fa9\u767c\u3002\u5728\u672c\u7814\u7a7610\u4f8b\u651c\u5e36\u6b64\u7279\u5f81\u7684\u60a3\u8005\u4e2d\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642\u7684\u5206\u5b50\u5b78\u7de9\u89e3\u7387\u9ad8\u905490%\uff089\\\/10\uff09\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5291\u91cf\u5316\u7642\u8010\u53d7\u6027\u826f\u597d\u3002\u5e38\u898b\u7684\uff08\u767c\u751f\u7387>15%\uff093\u7d1a\u6216\u4ee5\u4e0a\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u70ba\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\u75c7\uff0863.6%\uff09\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\uff0856.4%\uff09\u3001\u767d\u7d30\u80de\u6e1b\u5c11\u75c7\uff0854.5%\uff09\u3001\u8ca7\u8840\uff0849.1%\uff09\u3001\u80ba\u708e\uff0830.9%\uff09\u3001\u4f4e\u9240\u8840\u75c7\uff0820%\uff09\u548c\u809d\u529f\u80fd\u7570\u5e38\uff0816.4%\uff09\u3002 \u7d50\u8ad6\uff1a\u5728\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6cbb\u7642\u7684\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\uff0c\u81f3\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642MRD\u9670\u6027CR\u7387\u905464.2%\uff0c\u4e26\u986f\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u3002 Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations\u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u60272\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08CML-CP\uff09\uff0c\u5305\u62ec\u7121T315I\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08BAT\uff09\uff1a4\u5e74\u96a8\u8a2a\u671f\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a3788\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 \u2013 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e7412\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 \u2013 9:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388\u5831\u544a\u4eba\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388Highlights:\u6838\u5fc3\u8981\u9ede\uff1a \u8a72\u7814\u7a76\uff08NCT04126681\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u96a8\u6a5f\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7684\u95dc\u9375\u6ce8\u518aII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\\\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u672c\u5831\u544a\u70ba\u4e00\u98052023ASH\u5e74\u6703\u53e3\u982d\u5831\u544a\u7684\u7814\u7a76\u66f4\u65b0\u6578\u64da\u3002\u622a\u81f32025\u5e741\u670813\u65e5\uff0c\u5171\u6709144\u4f8bCML-CP\u60a3\u8005\u5165\u7d44\uff0c\u5176\u4e2d105\u4f8b\u70ba\u4e0d\u4f34T315I\u7a81\u8b8a\u60a3\u8005\u3002 \u5728\u672c\u7814\u7a76\u4e2d\uff0c\u60a3\u8005\u88ab\u6309\u71672:1 \u6bd4\u4f8b\u96a8\u6a5f\u5206\u7d44\u9032\u5165\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548c\u7814\u7a76\u8005\u6c7a\u5b9a\u7684\u73fe\u6709\u6700\u4f73\u6cbb\u7642\uff08BAT\uff09\u5c0d\u7167\u7d44\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u7121\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u3002 \u7642\u6548\u6578\u64da\uff1a \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u986f\u8457\u9577\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CMP-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba21.22\u500b\u6708\u548c2.86\u500b\u6708\uff08P < 0.001\uff09\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba11.96 \u548c3.14\u500b\u6708\uff08P = 0.0159\uff09\u3002 \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u5176\u4ed6\u7642\u6548\u6307\u6a19\u986f\u8457\u9ad8\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u5b8c\u5168\u8840\u6db2\u5b78\u7de9\u89e3(CHR)\u7387\u5206\u5225\u70ba85% \u548c34.8%\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u5206\u5225\u70ba37.5%\u548c18.9%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u5206\u5225\u70ba29.5%\u548c8.1%\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0cCHR\u5206\u5225\u70ba82.1% \u548c50.0%\uff0cCCyR\u5206\u5225\u70ba25.8%\u548c20.7%\uff0cMMR\u5206\u5225\u70ba16.1%\u548c 10.3%\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u5728\u4f34\u6216\u4e0d\u4f34T315I\u7a81\u8b8a\u7684CML-CP\u60a3\u8005\u4e2d\u5747\u5c55\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u6db2\u5b78\u6bd2\u6027\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6cbb\u7642\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\\\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u53d7\u8a66\u8005\uff0c\u5305\u62ec\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u6642\uff0c\u8f03BAT\u6cbb\u7642\u7d44\u5c55\u793a\u51fa\u660e\u986f\u6cbb\u7642\u512a\u52e2\u3002 Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML)\u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642CP-CML\u60a3\u8005\u6578\u64da\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a3782\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 - 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e74 12\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 - 9:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388\u5831\u544a\u4eba\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388\u6838\u5fc3\u8981\u9ede\uff1a\u8a72\u7814\u7a76\uff08ChiCTR2200061655\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u9694\u65e5\u53e3\u670d40mg\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u65e2\u5f80\u4f7f\u7528\u904e\u4e00\u7a2eTKI\u6cbb\u7642\u5f8c\u8010\u85e5\u6216\u4e0d\u8010\u53d7\uff08\u5305\u62ec\u4f0a\u99ac\u66ff\u5c3c\u3001\u6c1f\u99ac\u66ff\u5c3c\u3001\u5c3c\u6d1b\u66ff\u5c3c\u53ca\u9054\u6c99\u66ff\u5c3c\u7b49\uff09\u7684\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u622a\u81f32025\u5e747\u670824\u65e5\uff0c\u5171\u5165\u7d44\u975eT315I \u7a81\u8b8a\u7684CP-CML \u60a3\u800547\u4f8b\u3002 \u7642\u6548\u6578\u64da\uff1a \u622a\u81f32025\u5e747\u670824\u65e5\uff0c39\u4f8b\uff0883.0%\uff09\u60a3\u8005\u63a5\u53d7\u4e86\u81f3\u5c111\u6b21\u7642\u6548\u8a55\u4f30\uff0c36\u4f8b\uff0876.6%\uff09\u63a5\u53d7\u4e86\u81f3\u5c112\u6b21\u7642\u6548\u8a55\u4f30\uff0c34\u4f8b\uff0872.3%\uff09\u63a5\u53d7\u4e86\u81f3\u5c113\u6b21\u7642\u6548\u8a55\u4f30\u30022\u4f8b\u60a3\u8005\u5c1a\u672a\u9032\u884c\u9996\u6b21\u7642\u6548\u8a55\u4f30\u3002 \u81f3\u622a\u6b62\u65e5\u671f\uff0c71.8%\uff0828\\\/39\uff09\u7684\u60a3\u8005\u7372CCyR\uff0c43.6%\uff0817\\\/39\uff09\u7372MMR\u3002\u7b2c6\u30019\u300112\u300115\u300118\u300121\u300124\u500b\u5468\u671f\u8a55\u4f30\u7684CCyR\u7387\u548cMMR\u7387\u5206\u5225\u70ba54.3%\u548c25.7%\u300166.7%\u548c33.3%\u300174.2%\u548c35.5%\u300184.6%\u548c46.2%\u300185.7% \u548c 47.6%\u300190.0% \u548c 60.0%\u300189.5% \u548c 57.9%\u3002\u63d0\u793a\u7642\u6548\u96a8\u7528\u85e5\u6642\u9593\u5ef6\u9577\u800c\u7de9\u89e3\u9010\u6f38\u52a0\u6df1\u3002 \u572839\u4f8b\u7642\u6548\u53ef\u8a55\u4f30\u7684\u60a3\u8005\u4e2d\uff0c\u670930\u4f8b\u60a3\u8005\u65e2\u5f80\u4ee5\u4e8c\u4ee3TKI\u4f5c\u70ba\u4e00\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d76.7%\uff0823\\\/30\uff09\u7372\u5f97CCyR\uff0c43.3%\uff0813\\\/30\uff09\u7372\u5f97MMR\uff1b\u5728\u65e2\u5f80\u63a5\u53d7\u4f0a\u99ac\u66ff\u5c3c\u6cbb\u7642\u76849\u4f8b\u60a3\u8005\u4e2d\uff0c55.6%\uff085\\\/9\uff09\u7372\u5f97CCyR\uff0c44.4%\uff084\\\/9\uff09\u7372\u5f97MMR\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u4e2d\u4f4d\uff08\u5340\u9593\uff09\u6cbb\u7642\u6642\u959316.0\uff081-18\uff09\u500b\u6708\u3002\u5171\u670942\u4f8b\uff0889.4%\uff09\u60a3\u8005\u767c\u751f\u4e86\u4efb\u4f55\u7d1a\u5225\u7684\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u4e8b\u4ef6\uff08TRAEs\uff09\uff0c\u5176\u4e2d21\u4f8b\uff0844.7%\uff09\u767c\u751f\u4e86\u22653\u7d1aTRAEs\uff0c6\u4f8b\uff0812.8%\uff09\u767c\u751f\u4e86\u8207\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dc\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\uff08SAEs\uff09\u3002\u22653\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u53cd\u61c9\u5305\u62ec\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.6%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0825.5%\uff09\u548c\u8ca7\u8840\uff088.5%\uff09\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dcSAEs\u5305\u62ec\u8840\u5c0f\u677f\u8a08\u6578\u6e1b\u5c11\uff086.4%\uff09\u3001\u8ca7\u8840\u3001\u9aa8\u9ad3\u6291\u5236\u548c\u767c\u71b1\uff08\u54042.1%\uff09\u3002\u7121\u6b7b\u4ea1\u5831\u544a\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u80fd\u70ba\u4e8c\u7ddaCP-CML\u60a3\u8005\u63d0\u4f9b\u4e00\u7a2e\u5b89\u5168\u6709\u6548\u7684\u6cbb\u7642\u9078\u64c7\uff0c\u5c24\u5176\u662f\u5c0d\u65bc\u4e00\u7dda\u4f7f\u7528\u4e8c\u4ee3\u00a0TKIs\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\u3002 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c\u00a0MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u65e2\u5f80\u7d93\u904e\u81f3\u5c11\u5305\u542b\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u4e00\u7a2e\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\\\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\\\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbbCLL\\\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u6cbb\u7642\u521d\u6cbbCLL\\\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u3001\u6b50\u6d32EMA\u8207\u4e2d\u570bCDE\u540c\u6b65\u6279\u51c6\u958b\u5c55\u7684\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff09\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u7cfb\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378515#breadcrumb\"},\"inLanguage\":\"zh-TW\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378515\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378515#primaryimage\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/Ascentage_APAC_Logo-12.jpg\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/Ascentage_APAC_Logo-12.jpg\",\"width\":400,\"height\":150},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?p=378515#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u9996\u9801\",\"item\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u30102025 ASH\u3011\u4e9e\u76db\u91ab\u85e5\u8010\u7acb\u514b\u00ae\u591a\u9805\u7814\u7a76\u5165\u9078\uff0cPOLARIS-1\u7814\u7a76\u6578\u64da\u9996\u6b21\u767c\u5e03\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#website\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"description\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4\",\"publisher\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"zh-TW\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#organization\",\"name\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"contentUrl\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo-150.png\",\"width\":150,\"height\":150,\"caption\":\"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831\"},\"image\":{\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pingtungnews\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/#\\\/schema\\\/person\\\/683b937f29ec1537972f6c41e22a2cf3\",\"name\":\"\u7f8e\u901a\u793e\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"zh-TW\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g\",\"caption\":\"\u7f8e\u901a\u793e\"},\"url\":\"https:\\\/\\\/pingtungtimes.com.tw\\\/?author=16\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30102025 ASH\u3011\u4e9e\u76db\u91ab\u85e5\u8010\u7acb\u514b\u00ae\u591a\u9805\u7814\u7a76\u5165\u9078\uff0cPOLARIS-1\u7814\u7a76\u6578\u64da\u9996\u6b21\u767c\u5e03 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2025\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ --\u00a0\u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u6709\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c8\u5e74\u5165\u9078ASH\u5e74\u6703\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u00ae\u3001\u5229\u751f\u59a5\u00ae\u3001APG-5918\uff09\u6709\u591a\u9805\u81e8\u5e8a\u548c\u81e8\u5e8a\u524d\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5176\u4e2d\u4e00\u9805\u7372\u53e3\u982d\u5831\u544a\u3002 \u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u3002\u5176\u5728\u4e2d\u570b\u7684\u5546\u696d\u5316\u63a8\u5ee3\u7531\u4e9e\u76db\u91ab\u85e5\u548c\u4fe1\u9054\u751f\u7269\u5171\u540c\u8ca0\u8cac\u3002\u516c\u53f8\u5c07\u5728\u6b64\u6b21ASH\u5e74\u6703\u4e0a\uff0c\u9996\u6b21\u767c\u5e03\u8010\u7acb\u514b\u00ae\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684\u5168\u7403III\u671f\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff09\u6700\u65b0\u6578\u64da\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5CML-CP\u60a3\u8005\u7684\u96a8\u6a5f\u5c0d\u7167\u6ce8\u518aII\u671f\u7814\u7a76\u76844\u5e74\u96a8\u8a2a\u6578\u64da\u3001\u548c\u5176\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCML-CP\u60a3\u8005\u7684\u6578\u64da\u4e5f\u5c07\u5728\u6b64\u6b21\u6703\u8b70\u4e0a\u66f4\u65b0\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u6703\u662f\u5168\u7403\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u5b78\u8853\u76db\u6703\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u84cb\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7642\u7814\u7a76\u3002\u7b2c67\u5c46ASH\u5e74\u6703\u5c07\u65bc\u7576\u5730\u6642\u95932025\u5e7412\u67086\u65e5\u81f39\u65e5\u9593\u5728\u7f8e\u570b\u4f5b\u7f85\u88e1\u9054\u5dde\u5967\u862d\u591a\u5e02\u4ee5\u7dda\u4e0b\u7d50\u5408\u7dda\u4e0a\u7684\u5f62\u5f0f\u8209\u884c\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u4eca\u5e74\u5c07\u662f\u8010\u7acb\u514b\u00ae\u9023\u7e8c\u7b2c8\u5e74\u5728ASH\u5e74\u6703\u4e0a\u5c55\u793a\u6700\u65b0\u81e8\u5e8a\u9032\u5c55\uff0c\u518d\u4e00\u6b21\u9ad4\u73fe\u4e86\u570b\u969b\u8840\u6db2\u5b78\u754c\u5c0d\u8010\u7acb\u514b\u00ae\u7684\u5de8\u5927\u8a8d\u53ef\u3002\u76ee\u524d\uff0c\u8a72\u54c1\u7a2e\u67093\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u3002\u6b64\u5916\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u91cd\u9ede\u54c1\u7a2e\u6709\u591a\u9805\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5145\u5206\u986f\u73fe\u4e86\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u548c\u958b\u767c\u5be6\u529b\u3002\u6211\u5011\u671f\u5f85\u5728\u5f8c\u7e8c\u6703\u8b70\u671f\u9593\u8207\u5927\u5bb6\u5206\u4eab\u76f8\u95dc\u7814\u7a76\u7684\u8a73\u5be6\u6578\u64da\u3002\u672a\u4f86\uff0c\u4e9e\u76db\u91ab\u85e5\u5c07\u9032\u4e00\u6b65\u52a0\u901f\u63a8\u9032\u81e8\u5e8a\u958b\u767c\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d ASH 2025\u4e9e\u76db\u91ab\u85e5\u7522\u54c1\u76f8\u95dc\u7814\u7a76\u4e00\u89bd\uff1a \u5c55\u793a\u5f62\u5f0f \u54c1\u7a2e \u6458\u8981\u6a19\u984c \u7de8\u865f \u53e3\u982d\u5831\u544a \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis) \u4e00\u9805\u95dc\u65bc\u5229\u6c99\u6258\u514b\u62c9\u55ae\u85e5\u6cbb\u7642\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08BTKi\uff09\u6cbb\u7642\u5931\u6557\u7684\u5fa9\u767c\/\u96e3\u6cbb\u6027\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/ \u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u6ce8\u518a\u6027II\u671f\u7814\u7a76\u7d50\u679c 88 \u58c1\u5831\u5c55\u793a \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 Results of the APG2575AU101 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax\u2013exposed myeloid malignancies \u5229\u6c99\u6258\u514b\u62c9\u806f\u5408\u963f\u624e\u80de\u7518\u6cbb\u7642\u521d\u6cbb\u6216\u65e2\u5f80\u4f7f\u7528\u904e\u7dad\u5948\u6258\u514b\u7684\u9ad3\u7cfb\u816b\u7624\u7684\u81e8\u5e8a\u7814\u7a76\uff08APG2575AU101\uff09\u7d50\u679c 1641 \u5967\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Results of POLARIS-1, a global phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) \u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684 \u5168\u7403III\u671f\u7814\u7a76POLARIS-1\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c 1574 Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations \u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u60272\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08CML-CP\uff09\uff0c \u5305\u62ec\u7121T315I\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08BAT\uff09\uff1a4\u5e74\u96a8\u8a2a\u671f 3788 Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML) \u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u6578\u64da 3782 Preclinical and clinical Study of olverembatinib in patients with myeloid\/lymphoid neoplasms with FGFR1 rearrangement \u5967\u96f7\u5df4\u66ff\u5c3c\u7684\u81e8\u5e8a\u524d\u8207\u81e8\u5e8a\u7814\u7a76\uff1a\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\/\u6dcb\u5df4\u816b\u7624 1979 Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice report \u5967\u96f7\u5df4\u66ff\u5c3c\u4ecb\u5c0e\u7684\u6df1\u5ea6\u7de9\u89e3\u63d0\u5347\u7570\u57fa\u56e0\u5e72\u7d30\u80de\u79fb\u690d\u5728\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u6025\u8b8a\u671f\u60a3\u8005\u4e2d\u7684\u7642\u6548\uff1a \u9996\u4efd\u771f\u5be6\u4e16\u754c\u5be6\u8e10\u5831\u544a 1999 The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, control trial \u5c0d\u65bc\u65e2\u5f80\u63a5\u53d7\u904e\u81f3\u5c11\u5169\u7a2eTKI\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u6027\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\uff0c\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u8207\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a \u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u5c0d\u7167\u7814\u7a76 3779 Clinical and molecular features associated with glucolipid metabolic disorders and cardio-\/cerebro-vascular adverse events in CML patients receiving olverembatinib therapy \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u60a3\u8005\u51fa\u73fe\u7cd6\u8102\u4ee3\u8b1d\u7d0a\u4e82\u53ca\u5fc3\/\u8166\u8840\u7ba1\u4e0d\u826f\u4e8b\u4ef6\u7684 \u81e8\u5e8a\u8207\u5206\u5b50\u7279\u5f81 5561 APG-5918 Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs\/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM) \u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\uff08EED\uff09\u6291\u5236\u5291APG-5918\u55ae\u85e5\u5728\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d\u4e86\u514d\u75ab\u8abf\u7bc0\u85e5\u7269\uff08IMiD\uff09\u8010\u85e5\u6027\u4e26\u986f\u793a\u4e86 \u8207IMiDs\/Cereblon E3\u9023\u63a5\u9176\u8abf\u7bc0\u5291\uff08CELMoDs\uff09\u7684\u5354\u540c\u6548\u61c9 1528 \u5728\u7dda\u767c\u5e03 \u5967\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Single CAR-t infusion during front-line consolidation induces deep and sustained remissionin newly diagnosed adult ph+b- ALL: A prospective phase 2 study \u5c0d\u65bc\u65b0\u8a3a\u65b7\u7684\u6210\u4ebaPh\u967d\u6027B-ALL\u60a3\u8005\uff0c\u5728\u4e00\u7dda\u978f\u56fa\u6cbb\u7642\u968e\u6bb5\u9032\u884c\u55ae\u6b21CAR-T\u7d30\u80de\u8f38\u6ce8\uff0c\u53ef\u8a98\u5c0e\u6df1\u5ea6\u4e14\u6301\u4e45\u7684\u7de9\u89e3\uff1a\u4e00\u9805\u524d\u77bb\u6027II\u671f\u7814\u7a76\u3002 442 \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 BCL-2 inhibition in North American adult T-cell leukemia\/lymphoma: Preclinical insightsand early clinical outcomes BCL-2\u6291\u5236\u5291\u5728\u5317\u7f8e\u6210\u4ebaT\u7d30\u80de\u767d\u8840\u75c5\/\u6dcb\u5df4\u7624\u4e2d\u7684\u9776\u5411\u6cbb\u7642\uff1a\u81e8\u5e8a\u524d\u7814\u7a76\u8207\u65e9\u671f\u81e8\u5e8a\u7d50\u679c 3304 \u5967\u96f7\u5df4\u66ff\u5c3c\u5165\u90782025 ASH\u5e74\u6703\u7684\u4e3b\u8981\u7814\u7a76\u6458\u8981\u5982\u4e0b\uff1a\uff08\u5229\u6c99\u6258\u514b\u62c9\u5165\u9078ASH\u5e74\u6703\u7684\u6458\u8981\u8a73\u7d30\u4fe1\u606f\u53c3\u898b\u540c\u671f\u767c\u5e03\u7684\u53e6\u4e00\u7bc7\u65b0\u805e\u7a3f\uff09 Results of POLARIS-1, a global Phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)\u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684\u5168\u7403III\u671f\u7814\u7a76POLARIS-1\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a1574\u5206\u6703\u5834\uff1a613. \u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u540c\u7a2e\u79fb\u690d\u4ee5\u5916\u7684\u7642\u6cd5\uff1a\u58c1\u5831\u5c55\u793aI\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67086\u65e5\uff0c\u661f\u671f\u516d\uff0c\u4e0b\u534817:30 \u2013 19:30\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0a\u53486:30 \u2013 8:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388\u5831\u544a\u4eba\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388\u6838\u5fc3\u8981\u9ede\uff1a\u8a72\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff1bNCT06051409\uff09\u70ba\u4e00\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u5728\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff1b\u9006\u8f49\u9304qPCR\u65b9\u6cd5\u6aa2\u6e2cBCR-ABL1\/ABL1\u22640.01%\uff09\u9670\u6027\u7387\u3002 \u7642\u6548\u6578\u64da\uff1a \u622a\u81f32025\u5e747\u670818\u65e5\uff0c\u572853\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c50\u4f8b\u60a3\u8005\uff0894.3%\uff09\u5728\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5be6\u73fe\u4e86\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u6216CR\u4f34\u4e0d\u5b8c\u5168\u8840\u6db2\u5b78\u6062\u5fa9\uff0c\u6700\u4f73MRD\u9670\u6027\u7387\u548cMRD\u9670\u6027CR\u7387\u5206\u5225\u70ba66.0%\u548c64.2%\u3002 IKZF1plus\uff08\u5c24\u5176\u5408\u4e26BTG1\u7f3a\u5931\uff09\u662fB-ALL\u516c\u8a8d\u7684\u9ad8\u5371\u56e0\u7d20\uff0c\u5e38\u5c0e\u81f4\u5316\u7642\u8010\u85e5\u8207\u9ad8\u5fa9\u767c\u3002\u5728\u672c\u7814\u7a7610\u4f8b\u651c\u5e36\u6b64\u7279\u5f81\u7684\u60a3\u8005\u4e2d\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642\u7684\u5206\u5b50\u5b78\u7de9\u89e3\u7387\u9ad8\u905490%\uff089\/10\uff09\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5291\u91cf\u5316\u7642\u8010\u53d7\u6027\u826f\u597d\u3002\u5e38\u898b\u7684\uff08\u767c\u751f\u7387>15%\uff093\u7d1a\u6216\u4ee5\u4e0a\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u70ba\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\u75c7\uff0863.6%\uff09\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\uff0856.4%\uff09\u3001\u767d\u7d30\u80de\u6e1b\u5c11\u75c7\uff0854.5%\uff09\u3001\u8ca7\u8840\uff0849.1%\uff09\u3001\u80ba\u708e\uff0830.9%\uff09\u3001\u4f4e\u9240\u8840\u75c7\uff0820%\uff09\u548c\u809d\u529f\u80fd\u7570\u5e38\uff0816.4%\uff09\u3002 \u7d50\u8ad6\uff1a\u5728\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6cbb\u7642\u7684\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\uff0c\u81f3\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642MRD\u9670\u6027CR\u7387\u905464.2%\uff0c\u4e26\u986f\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u3002 Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations\u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u60272\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08CML-CP\uff09\uff0c\u5305\u62ec\u7121T315I\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08BAT\uff09\uff1a4\u5e74\u96a8\u8a2a\u671f\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a3788\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 \u2013 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e7412\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 \u2013 9:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388\u5831\u544a\u4eba\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388Highlights:\u6838\u5fc3\u8981\u9ede\uff1a \u8a72\u7814\u7a76\uff08NCT04126681\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u96a8\u6a5f\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7684\u95dc\u9375\u6ce8\u518aII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u672c\u5831\u544a\u70ba\u4e00\u98052023ASH\u5e74\u6703\u53e3\u982d\u5831\u544a\u7684\u7814\u7a76\u66f4\u65b0\u6578\u64da\u3002\u622a\u81f32025\u5e741\u670813\u65e5\uff0c\u5171\u6709144\u4f8bCML-CP\u60a3\u8005\u5165\u7d44\uff0c\u5176\u4e2d105\u4f8b\u70ba\u4e0d\u4f34T315I\u7a81\u8b8a\u60a3\u8005\u3002 \u5728\u672c\u7814\u7a76\u4e2d\uff0c\u60a3\u8005\u88ab\u6309\u71672:1 \u6bd4\u4f8b\u96a8\u6a5f\u5206\u7d44\u9032\u5165\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548c\u7814\u7a76\u8005\u6c7a\u5b9a\u7684\u73fe\u6709\u6700\u4f73\u6cbb\u7642\uff08BAT\uff09\u5c0d\u7167\u7d44\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u7121\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u3002 \u7642\u6548\u6578\u64da\uff1a \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u986f\u8457\u9577\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CMP-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba21.22\u500b\u6708\u548c2.86\u500b\u6708\uff08P < 0.001\uff09\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba11.96 \u548c3.14\u500b\u6708\uff08P = 0.0159\uff09\u3002 \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u5176\u4ed6\u7642\u6548\u6307\u6a19\u986f\u8457\u9ad8\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u5b8c\u5168\u8840\u6db2\u5b78\u7de9\u89e3(CHR)\u7387\u5206\u5225\u70ba85% \u548c34.8%\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u5206\u5225\u70ba37.5%\u548c18.9%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u5206\u5225\u70ba29.5%\u548c8.1%\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0cCHR\u5206\u5225\u70ba82.1% \u548c50.0%\uff0cCCyR\u5206\u5225\u70ba25.8%\u548c20.7%\uff0cMMR\u5206\u5225\u70ba16.1%\u548c 10.3%\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u5728\u4f34\u6216\u4e0d\u4f34T315I\u7a81\u8b8a\u7684CML-CP\u60a3\u8005\u4e2d\u5747\u5c55\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u6db2\u5b78\u6bd2\u6027\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6cbb\u7642\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u53d7\u8a66\u8005\uff0c\u5305\u62ec\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u6642\uff0c\u8f03BAT\u6cbb\u7642\u7d44\u5c55\u793a\u51fa\u660e\u986f\u6cbb\u7642\u512a\u52e2\u3002 Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML)\u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642CP-CML\u60a3\u8005\u6578\u64da\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a3782\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 - 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e74 12\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 - 9:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388\u5831\u544a\u4eba\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388\u6838\u5fc3\u8981\u9ede\uff1a\u8a72\u7814\u7a76\uff08ChiCTR2200061655\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u9694\u65e5\u53e3\u670d40mg\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u65e2\u5f80\u4f7f\u7528\u904e\u4e00\u7a2eTKI\u6cbb\u7642\u5f8c\u8010\u85e5\u6216\u4e0d\u8010\u53d7\uff08\u5305\u62ec\u4f0a\u99ac\u66ff\u5c3c\u3001\u6c1f\u99ac\u66ff\u5c3c\u3001\u5c3c\u6d1b\u66ff\u5c3c\u53ca\u9054\u6c99\u66ff\u5c3c\u7b49\uff09\u7684\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u622a\u81f32025\u5e747\u670824\u65e5\uff0c\u5171\u5165\u7d44\u975eT315I \u7a81\u8b8a\u7684CP-CML \u60a3\u800547\u4f8b\u3002 \u7642\u6548\u6578\u64da\uff1a \u622a\u81f32025\u5e747\u670824\u65e5\uff0c39\u4f8b\uff0883.0%\uff09\u60a3\u8005\u63a5\u53d7\u4e86\u81f3\u5c111\u6b21\u7642\u6548\u8a55\u4f30\uff0c36\u4f8b\uff0876.6%\uff09\u63a5\u53d7\u4e86\u81f3\u5c112\u6b21\u7642\u6548\u8a55\u4f30\uff0c34\u4f8b\uff0872.3%\uff09\u63a5\u53d7\u4e86\u81f3\u5c113\u6b21\u7642\u6548\u8a55\u4f30\u30022\u4f8b\u60a3\u8005\u5c1a\u672a\u9032\u884c\u9996\u6b21\u7642\u6548\u8a55\u4f30\u3002 \u81f3\u622a\u6b62\u65e5\u671f\uff0c71.8%\uff0828\/39\uff09\u7684\u60a3\u8005\u7372CCyR\uff0c43.6%\uff0817\/39\uff09\u7372MMR\u3002\u7b2c6\u30019\u300112\u300115\u300118\u300121\u300124\u500b\u5468\u671f\u8a55\u4f30\u7684CCyR\u7387\u548cMMR\u7387\u5206\u5225\u70ba54.3%\u548c25.7%\u300166.7%\u548c33.3%\u300174.2%\u548c35.5%\u300184.6%\u548c46.2%\u300185.7% \u548c 47.6%\u300190.0% \u548c 60.0%\u300189.5% \u548c 57.9%\u3002\u63d0\u793a\u7642\u6548\u96a8\u7528\u85e5\u6642\u9593\u5ef6\u9577\u800c\u7de9\u89e3\u9010\u6f38\u52a0\u6df1\u3002 \u572839\u4f8b\u7642\u6548\u53ef\u8a55\u4f30\u7684\u60a3\u8005\u4e2d\uff0c\u670930\u4f8b\u60a3\u8005\u65e2\u5f80\u4ee5\u4e8c\u4ee3TKI\u4f5c\u70ba\u4e00\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d76.7%\uff0823\/30\uff09\u7372\u5f97CCyR\uff0c43.3%\uff0813\/30\uff09\u7372\u5f97MMR\uff1b\u5728\u65e2\u5f80\u63a5\u53d7\u4f0a\u99ac\u66ff\u5c3c\u6cbb\u7642\u76849\u4f8b\u60a3\u8005\u4e2d\uff0c55.6%\uff085\/9\uff09\u7372\u5f97CCyR\uff0c44.4%\uff084\/9\uff09\u7372\u5f97MMR\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u4e2d\u4f4d\uff08\u5340\u9593\uff09\u6cbb\u7642\u6642\u959316.0\uff081-18\uff09\u500b\u6708\u3002\u5171\u670942\u4f8b\uff0889.4%\uff09\u60a3\u8005\u767c\u751f\u4e86\u4efb\u4f55\u7d1a\u5225\u7684\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u4e8b\u4ef6\uff08TRAEs\uff09\uff0c\u5176\u4e2d21\u4f8b\uff0844.7%\uff09\u767c\u751f\u4e86\u22653\u7d1aTRAEs\uff0c6\u4f8b\uff0812.8%\uff09\u767c\u751f\u4e86\u8207\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dc\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\uff08SAEs\uff09\u3002\u22653\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u53cd\u61c9\u5305\u62ec\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.6%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0825.5%\uff09\u548c\u8ca7\u8840\uff088.5%\uff09\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dcSAEs\u5305\u62ec\u8840\u5c0f\u677f\u8a08\u6578\u6e1b\u5c11\uff086.4%\uff09\u3001\u8ca7\u8840\u3001\u9aa8\u9ad3\u6291\u5236\u548c\u767c\u71b1\uff08\u54042.1%\uff09\u3002\u7121\u6b7b\u4ea1\u5831\u544a\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u80fd\u70ba\u4e8c\u7ddaCP-CML\u60a3\u8005\u63d0\u4f9b\u4e00\u7a2e\u5b89\u5168\u6709\u6548\u7684\u6cbb\u7642\u9078\u64c7\uff0c\u5c24\u5176\u662f\u5c0d\u65bc\u4e00\u7dda\u4f7f\u7528\u4e8c\u4ee3\u00a0TKIs\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\u3002 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c\u00a0MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u65e2\u5f80\u7d93\u904e\u81f3\u5c11\u5305\u542b\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u4e00\u7a2e\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u3001\u6b50\u6d32EMA\u8207\u4e2d\u570bCDE\u540c\u6b65\u6279\u51c6\u958b\u5c55\u7684\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff09\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u7cfb\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pingtungtimes.com.tw\/?p=378515","og_locale":"zh_TW","og_type":"article","og_title":"\u30102025 ASH\u3011\u4e9e\u76db\u91ab\u85e5\u8010\u7acb\u514b\u00ae\u591a\u9805\u7814\u7a76\u5165\u9078\uff0cPOLARIS-1\u7814\u7a76\u6578\u64da\u9996\u6b21\u767c\u5e03 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","og_description":"\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2025\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ --\u00a0\u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u6709\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c8\u5e74\u5165\u9078ASH\u5e74\u6703\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u00ae\u3001\u5229\u751f\u59a5\u00ae\u3001APG-5918\uff09\u6709\u591a\u9805\u81e8\u5e8a\u548c\u81e8\u5e8a\u524d\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5176\u4e2d\u4e00\u9805\u7372\u53e3\u982d\u5831\u544a\u3002 \u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u3002\u5176\u5728\u4e2d\u570b\u7684\u5546\u696d\u5316\u63a8\u5ee3\u7531\u4e9e\u76db\u91ab\u85e5\u548c\u4fe1\u9054\u751f\u7269\u5171\u540c\u8ca0\u8cac\u3002\u516c\u53f8\u5c07\u5728\u6b64\u6b21ASH\u5e74\u6703\u4e0a\uff0c\u9996\u6b21\u767c\u5e03\u8010\u7acb\u514b\u00ae\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684\u5168\u7403III\u671f\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff09\u6700\u65b0\u6578\u64da\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5CML-CP\u60a3\u8005\u7684\u96a8\u6a5f\u5c0d\u7167\u6ce8\u518aII\u671f\u7814\u7a76\u76844\u5e74\u96a8\u8a2a\u6578\u64da\u3001\u548c\u5176\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCML-CP\u60a3\u8005\u7684\u6578\u64da\u4e5f\u5c07\u5728\u6b64\u6b21\u6703\u8b70\u4e0a\u66f4\u65b0\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u6703\u662f\u5168\u7403\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u5b78\u8853\u76db\u6703\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u84cb\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7642\u7814\u7a76\u3002\u7b2c67\u5c46ASH\u5e74\u6703\u5c07\u65bc\u7576\u5730\u6642\u95932025\u5e7412\u67086\u65e5\u81f39\u65e5\u9593\u5728\u7f8e\u570b\u4f5b\u7f85\u88e1\u9054\u5dde\u5967\u862d\u591a\u5e02\u4ee5\u7dda\u4e0b\u7d50\u5408\u7dda\u4e0a\u7684\u5f62\u5f0f\u8209\u884c\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u4eca\u5e74\u5c07\u662f\u8010\u7acb\u514b\u00ae\u9023\u7e8c\u7b2c8\u5e74\u5728ASH\u5e74\u6703\u4e0a\u5c55\u793a\u6700\u65b0\u81e8\u5e8a\u9032\u5c55\uff0c\u518d\u4e00\u6b21\u9ad4\u73fe\u4e86\u570b\u969b\u8840\u6db2\u5b78\u754c\u5c0d\u8010\u7acb\u514b\u00ae\u7684\u5de8\u5927\u8a8d\u53ef\u3002\u76ee\u524d\uff0c\u8a72\u54c1\u7a2e\u67093\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u3002\u6b64\u5916\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u91cd\u9ede\u54c1\u7a2e\u6709\u591a\u9805\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5145\u5206\u986f\u73fe\u4e86\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u548c\u958b\u767c\u5be6\u529b\u3002\u6211\u5011\u671f\u5f85\u5728\u5f8c\u7e8c\u6703\u8b70\u671f\u9593\u8207\u5927\u5bb6\u5206\u4eab\u76f8\u95dc\u7814\u7a76\u7684\u8a73\u5be6\u6578\u64da\u3002\u672a\u4f86\uff0c\u4e9e\u76db\u91ab\u85e5\u5c07\u9032\u4e00\u6b65\u52a0\u901f\u63a8\u9032\u81e8\u5e8a\u958b\u767c\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d ASH 2025\u4e9e\u76db\u91ab\u85e5\u7522\u54c1\u76f8\u95dc\u7814\u7a76\u4e00\u89bd\uff1a \u5c55\u793a\u5f62\u5f0f \u54c1\u7a2e \u6458\u8981\u6a19\u984c \u7de8\u865f \u53e3\u982d\u5831\u544a \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis) \u4e00\u9805\u95dc\u65bc\u5229\u6c99\u6258\u514b\u62c9\u55ae\u85e5\u6cbb\u7642\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08BTKi\uff09\u6cbb\u7642\u5931\u6557\u7684\u5fa9\u767c\/\u96e3\u6cbb\u6027\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/ \u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u6ce8\u518a\u6027II\u671f\u7814\u7a76\u7d50\u679c 88 \u58c1\u5831\u5c55\u793a \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 Results of the APG2575AU101 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax\u2013exposed myeloid malignancies \u5229\u6c99\u6258\u514b\u62c9\u806f\u5408\u963f\u624e\u80de\u7518\u6cbb\u7642\u521d\u6cbb\u6216\u65e2\u5f80\u4f7f\u7528\u904e\u7dad\u5948\u6258\u514b\u7684\u9ad3\u7cfb\u816b\u7624\u7684\u81e8\u5e8a\u7814\u7a76\uff08APG2575AU101\uff09\u7d50\u679c 1641 \u5967\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Results of POLARIS-1, a global phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) \u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684 \u5168\u7403III\u671f\u7814\u7a76POLARIS-1\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c 1574 Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations \u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u60272\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08CML-CP\uff09\uff0c \u5305\u62ec\u7121T315I\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08BAT\uff09\uff1a4\u5e74\u96a8\u8a2a\u671f 3788 Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML) \u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u6578\u64da 3782 Preclinical and clinical Study of olverembatinib in patients with myeloid\/lymphoid neoplasms with FGFR1 rearrangement \u5967\u96f7\u5df4\u66ff\u5c3c\u7684\u81e8\u5e8a\u524d\u8207\u81e8\u5e8a\u7814\u7a76\uff1a\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\/\u6dcb\u5df4\u816b\u7624 1979 Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice report \u5967\u96f7\u5df4\u66ff\u5c3c\u4ecb\u5c0e\u7684\u6df1\u5ea6\u7de9\u89e3\u63d0\u5347\u7570\u57fa\u56e0\u5e72\u7d30\u80de\u79fb\u690d\u5728\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u6025\u8b8a\u671f\u60a3\u8005\u4e2d\u7684\u7642\u6548\uff1a \u9996\u4efd\u771f\u5be6\u4e16\u754c\u5be6\u8e10\u5831\u544a 1999 The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, control trial \u5c0d\u65bc\u65e2\u5f80\u63a5\u53d7\u904e\u81f3\u5c11\u5169\u7a2eTKI\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u6027\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\uff0c\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u8207\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a \u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u5c0d\u7167\u7814\u7a76 3779 Clinical and molecular features associated with glucolipid metabolic disorders and cardio-\/cerebro-vascular adverse events in CML patients receiving olverembatinib therapy \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u60a3\u8005\u51fa\u73fe\u7cd6\u8102\u4ee3\u8b1d\u7d0a\u4e82\u53ca\u5fc3\/\u8166\u8840\u7ba1\u4e0d\u826f\u4e8b\u4ef6\u7684 \u81e8\u5e8a\u8207\u5206\u5b50\u7279\u5f81 5561 APG-5918 Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs\/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM) \u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\uff08EED\uff09\u6291\u5236\u5291APG-5918\u55ae\u85e5\u5728\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d\u4e86\u514d\u75ab\u8abf\u7bc0\u85e5\u7269\uff08IMiD\uff09\u8010\u85e5\u6027\u4e26\u986f\u793a\u4e86 \u8207IMiDs\/Cereblon E3\u9023\u63a5\u9176\u8abf\u7bc0\u5291\uff08CELMoDs\uff09\u7684\u5354\u540c\u6548\u61c9 1528 \u5728\u7dda\u767c\u5e03 \u5967\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Single CAR-t infusion during front-line consolidation induces deep and sustained remissionin newly diagnosed adult ph+b- ALL: A prospective phase 2 study \u5c0d\u65bc\u65b0\u8a3a\u65b7\u7684\u6210\u4ebaPh\u967d\u6027B-ALL\u60a3\u8005\uff0c\u5728\u4e00\u7dda\u978f\u56fa\u6cbb\u7642\u968e\u6bb5\u9032\u884c\u55ae\u6b21CAR-T\u7d30\u80de\u8f38\u6ce8\uff0c\u53ef\u8a98\u5c0e\u6df1\u5ea6\u4e14\u6301\u4e45\u7684\u7de9\u89e3\uff1a\u4e00\u9805\u524d\u77bb\u6027II\u671f\u7814\u7a76\u3002 442 \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 BCL-2 inhibition in North American adult T-cell leukemia\/lymphoma: Preclinical insightsand early clinical outcomes BCL-2\u6291\u5236\u5291\u5728\u5317\u7f8e\u6210\u4ebaT\u7d30\u80de\u767d\u8840\u75c5\/\u6dcb\u5df4\u7624\u4e2d\u7684\u9776\u5411\u6cbb\u7642\uff1a\u81e8\u5e8a\u524d\u7814\u7a76\u8207\u65e9\u671f\u81e8\u5e8a\u7d50\u679c 3304 \u5967\u96f7\u5df4\u66ff\u5c3c\u5165\u90782025 ASH\u5e74\u6703\u7684\u4e3b\u8981\u7814\u7a76\u6458\u8981\u5982\u4e0b\uff1a\uff08\u5229\u6c99\u6258\u514b\u62c9\u5165\u9078ASH\u5e74\u6703\u7684\u6458\u8981\u8a73\u7d30\u4fe1\u606f\u53c3\u898b\u540c\u671f\u767c\u5e03\u7684\u53e6\u4e00\u7bc7\u65b0\u805e\u7a3f\uff09 Results of POLARIS-1, a global Phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)\u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684\u5168\u7403III\u671f\u7814\u7a76POLARIS-1\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a1574\u5206\u6703\u5834\uff1a613. \u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u540c\u7a2e\u79fb\u690d\u4ee5\u5916\u7684\u7642\u6cd5\uff1a\u58c1\u5831\u5c55\u793aI\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67086\u65e5\uff0c\u661f\u671f\u516d\uff0c\u4e0b\u534817:30 \u2013 19:30\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0a\u53486:30 \u2013 8:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388\u5831\u544a\u4eba\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388\u6838\u5fc3\u8981\u9ede\uff1a\u8a72\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff1bNCT06051409\uff09\u70ba\u4e00\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u5728\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff1b\u9006\u8f49\u9304qPCR\u65b9\u6cd5\u6aa2\u6e2cBCR-ABL1\/ABL1\u22640.01%\uff09\u9670\u6027\u7387\u3002 \u7642\u6548\u6578\u64da\uff1a \u622a\u81f32025\u5e747\u670818\u65e5\uff0c\u572853\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c50\u4f8b\u60a3\u8005\uff0894.3%\uff09\u5728\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5be6\u73fe\u4e86\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u6216CR\u4f34\u4e0d\u5b8c\u5168\u8840\u6db2\u5b78\u6062\u5fa9\uff0c\u6700\u4f73MRD\u9670\u6027\u7387\u548cMRD\u9670\u6027CR\u7387\u5206\u5225\u70ba66.0%\u548c64.2%\u3002 IKZF1plus\uff08\u5c24\u5176\u5408\u4e26BTG1\u7f3a\u5931\uff09\u662fB-ALL\u516c\u8a8d\u7684\u9ad8\u5371\u56e0\u7d20\uff0c\u5e38\u5c0e\u81f4\u5316\u7642\u8010\u85e5\u8207\u9ad8\u5fa9\u767c\u3002\u5728\u672c\u7814\u7a7610\u4f8b\u651c\u5e36\u6b64\u7279\u5f81\u7684\u60a3\u8005\u4e2d\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642\u7684\u5206\u5b50\u5b78\u7de9\u89e3\u7387\u9ad8\u905490%\uff089\/10\uff09\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5291\u91cf\u5316\u7642\u8010\u53d7\u6027\u826f\u597d\u3002\u5e38\u898b\u7684\uff08\u767c\u751f\u7387>15%\uff093\u7d1a\u6216\u4ee5\u4e0a\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u70ba\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\u75c7\uff0863.6%\uff09\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\uff0856.4%\uff09\u3001\u767d\u7d30\u80de\u6e1b\u5c11\u75c7\uff0854.5%\uff09\u3001\u8ca7\u8840\uff0849.1%\uff09\u3001\u80ba\u708e\uff0830.9%\uff09\u3001\u4f4e\u9240\u8840\u75c7\uff0820%\uff09\u548c\u809d\u529f\u80fd\u7570\u5e38\uff0816.4%\uff09\u3002 \u7d50\u8ad6\uff1a\u5728\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6cbb\u7642\u7684\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\uff0c\u81f3\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642MRD\u9670\u6027CR\u7387\u905464.2%\uff0c\u4e26\u986f\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u3002 Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations\u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u60272\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08CML-CP\uff09\uff0c\u5305\u62ec\u7121T315I\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08BAT\uff09\uff1a4\u5e74\u96a8\u8a2a\u671f\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a3788\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 \u2013 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e7412\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 \u2013 9:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388\u5831\u544a\u4eba\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388Highlights:\u6838\u5fc3\u8981\u9ede\uff1a \u8a72\u7814\u7a76\uff08NCT04126681\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u96a8\u6a5f\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7684\u95dc\u9375\u6ce8\u518aII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u672c\u5831\u544a\u70ba\u4e00\u98052023ASH\u5e74\u6703\u53e3\u982d\u5831\u544a\u7684\u7814\u7a76\u66f4\u65b0\u6578\u64da\u3002\u622a\u81f32025\u5e741\u670813\u65e5\uff0c\u5171\u6709144\u4f8bCML-CP\u60a3\u8005\u5165\u7d44\uff0c\u5176\u4e2d105\u4f8b\u70ba\u4e0d\u4f34T315I\u7a81\u8b8a\u60a3\u8005\u3002 \u5728\u672c\u7814\u7a76\u4e2d\uff0c\u60a3\u8005\u88ab\u6309\u71672:1 \u6bd4\u4f8b\u96a8\u6a5f\u5206\u7d44\u9032\u5165\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548c\u7814\u7a76\u8005\u6c7a\u5b9a\u7684\u73fe\u6709\u6700\u4f73\u6cbb\u7642\uff08BAT\uff09\u5c0d\u7167\u7d44\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u7121\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u3002 \u7642\u6548\u6578\u64da\uff1a \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u986f\u8457\u9577\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CMP-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba21.22\u500b\u6708\u548c2.86\u500b\u6708\uff08P < 0.001\uff09\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba11.96 \u548c3.14\u500b\u6708\uff08P = 0.0159\uff09\u3002 \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u5176\u4ed6\u7642\u6548\u6307\u6a19\u986f\u8457\u9ad8\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u5b8c\u5168\u8840\u6db2\u5b78\u7de9\u89e3(CHR)\u7387\u5206\u5225\u70ba85% \u548c34.8%\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u5206\u5225\u70ba37.5%\u548c18.9%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u5206\u5225\u70ba29.5%\u548c8.1%\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0cCHR\u5206\u5225\u70ba82.1% \u548c50.0%\uff0cCCyR\u5206\u5225\u70ba25.8%\u548c20.7%\uff0cMMR\u5206\u5225\u70ba16.1%\u548c 10.3%\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u5728\u4f34\u6216\u4e0d\u4f34T315I\u7a81\u8b8a\u7684CML-CP\u60a3\u8005\u4e2d\u5747\u5c55\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u6db2\u5b78\u6bd2\u6027\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6cbb\u7642\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u53d7\u8a66\u8005\uff0c\u5305\u62ec\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u6642\uff0c\u8f03BAT\u6cbb\u7642\u7d44\u5c55\u793a\u51fa\u660e\u986f\u6cbb\u7642\u512a\u52e2\u3002 Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML)\u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642CP-CML\u60a3\u8005\u6578\u64da\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a3782\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 - 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e74 12\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 - 9:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388\u5831\u544a\u4eba\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388\u6838\u5fc3\u8981\u9ede\uff1a\u8a72\u7814\u7a76\uff08ChiCTR2200061655\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u9694\u65e5\u53e3\u670d40mg\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u65e2\u5f80\u4f7f\u7528\u904e\u4e00\u7a2eTKI\u6cbb\u7642\u5f8c\u8010\u85e5\u6216\u4e0d\u8010\u53d7\uff08\u5305\u62ec\u4f0a\u99ac\u66ff\u5c3c\u3001\u6c1f\u99ac\u66ff\u5c3c\u3001\u5c3c\u6d1b\u66ff\u5c3c\u53ca\u9054\u6c99\u66ff\u5c3c\u7b49\uff09\u7684\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u622a\u81f32025\u5e747\u670824\u65e5\uff0c\u5171\u5165\u7d44\u975eT315I \u7a81\u8b8a\u7684CP-CML \u60a3\u800547\u4f8b\u3002 \u7642\u6548\u6578\u64da\uff1a \u622a\u81f32025\u5e747\u670824\u65e5\uff0c39\u4f8b\uff0883.0%\uff09\u60a3\u8005\u63a5\u53d7\u4e86\u81f3\u5c111\u6b21\u7642\u6548\u8a55\u4f30\uff0c36\u4f8b\uff0876.6%\uff09\u63a5\u53d7\u4e86\u81f3\u5c112\u6b21\u7642\u6548\u8a55\u4f30\uff0c34\u4f8b\uff0872.3%\uff09\u63a5\u53d7\u4e86\u81f3\u5c113\u6b21\u7642\u6548\u8a55\u4f30\u30022\u4f8b\u60a3\u8005\u5c1a\u672a\u9032\u884c\u9996\u6b21\u7642\u6548\u8a55\u4f30\u3002 \u81f3\u622a\u6b62\u65e5\u671f\uff0c71.8%\uff0828\/39\uff09\u7684\u60a3\u8005\u7372CCyR\uff0c43.6%\uff0817\/39\uff09\u7372MMR\u3002\u7b2c6\u30019\u300112\u300115\u300118\u300121\u300124\u500b\u5468\u671f\u8a55\u4f30\u7684CCyR\u7387\u548cMMR\u7387\u5206\u5225\u70ba54.3%\u548c25.7%\u300166.7%\u548c33.3%\u300174.2%\u548c35.5%\u300184.6%\u548c46.2%\u300185.7% \u548c 47.6%\u300190.0% \u548c 60.0%\u300189.5% \u548c 57.9%\u3002\u63d0\u793a\u7642\u6548\u96a8\u7528\u85e5\u6642\u9593\u5ef6\u9577\u800c\u7de9\u89e3\u9010\u6f38\u52a0\u6df1\u3002 \u572839\u4f8b\u7642\u6548\u53ef\u8a55\u4f30\u7684\u60a3\u8005\u4e2d\uff0c\u670930\u4f8b\u60a3\u8005\u65e2\u5f80\u4ee5\u4e8c\u4ee3TKI\u4f5c\u70ba\u4e00\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d76.7%\uff0823\/30\uff09\u7372\u5f97CCyR\uff0c43.3%\uff0813\/30\uff09\u7372\u5f97MMR\uff1b\u5728\u65e2\u5f80\u63a5\u53d7\u4f0a\u99ac\u66ff\u5c3c\u6cbb\u7642\u76849\u4f8b\u60a3\u8005\u4e2d\uff0c55.6%\uff085\/9\uff09\u7372\u5f97CCyR\uff0c44.4%\uff084\/9\uff09\u7372\u5f97MMR\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u4e2d\u4f4d\uff08\u5340\u9593\uff09\u6cbb\u7642\u6642\u959316.0\uff081-18\uff09\u500b\u6708\u3002\u5171\u670942\u4f8b\uff0889.4%\uff09\u60a3\u8005\u767c\u751f\u4e86\u4efb\u4f55\u7d1a\u5225\u7684\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u4e8b\u4ef6\uff08TRAEs\uff09\uff0c\u5176\u4e2d21\u4f8b\uff0844.7%\uff09\u767c\u751f\u4e86\u22653\u7d1aTRAEs\uff0c6\u4f8b\uff0812.8%\uff09\u767c\u751f\u4e86\u8207\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dc\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\uff08SAEs\uff09\u3002\u22653\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u53cd\u61c9\u5305\u62ec\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.6%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0825.5%\uff09\u548c\u8ca7\u8840\uff088.5%\uff09\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dcSAEs\u5305\u62ec\u8840\u5c0f\u677f\u8a08\u6578\u6e1b\u5c11\uff086.4%\uff09\u3001\u8ca7\u8840\u3001\u9aa8\u9ad3\u6291\u5236\u548c\u767c\u71b1\uff08\u54042.1%\uff09\u3002\u7121\u6b7b\u4ea1\u5831\u544a\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u80fd\u70ba\u4e8c\u7ddaCP-CML\u60a3\u8005\u63d0\u4f9b\u4e00\u7a2e\u5b89\u5168\u6709\u6548\u7684\u6cbb\u7642\u9078\u64c7\uff0c\u5c24\u5176\u662f\u5c0d\u65bc\u4e00\u7dda\u4f7f\u7528\u4e8c\u4ee3\u00a0TKIs\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\u3002 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c\u00a0MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u65e2\u5f80\u7d93\u904e\u81f3\u5c11\u5305\u542b\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u4e00\u7a2e\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u3001\u6b50\u6d32EMA\u8207\u4e2d\u570bCDE\u540c\u6b65\u6279\u51c6\u958b\u5c55\u7684\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff09\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u7cfb\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002","og_url":"https:\/\/pingtungtimes.com.tw\/?p=378515","og_site_name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","article_publisher":"https:\/\/www.facebook.com\/pingtungnews","article_published_time":"2025-11-04T01:22:00+00:00","og_image":[{"width":1706,"height":960,"url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","type":"image\/jpeg"}],"author":"\u7f8e\u901a\u793e","twitter_card":"summary_large_image","twitter_misc":{"\u4f5c\u8005:":"\u7f8e\u901a\u793e","\u9810\u4f30\u95b1\u8b80\u6642\u9593":"3 \u5206\u9418"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/pingtungtimes.com.tw\/?p=378515#article","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=378515"},"author":{"name":"\u7f8e\u901a\u793e","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3"},"headline":"\u30102025 ASH\u3011\u4e9e\u76db\u91ab\u85e5\u8010\u7acb\u514b\u00ae\u591a\u9805\u7814\u7a76\u5165\u9078\uff0cPOLARIS-1\u7814\u7a76\u6578\u64da\u9996\u6b21\u767c\u5e03","datePublished":"2025-11-04T01:22:00+00:00","mainEntityOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=378515"},"wordCount":613,"publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=378515#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Ascentage_APAC_Logo-12.jpg","articleSection":["\u7f8e\u901a\u793e"],"inLanguage":"zh-TW"},{"@type":"WebPage","@id":"https:\/\/pingtungtimes.com.tw\/?p=378515","url":"https:\/\/pingtungtimes.com.tw\/?p=378515","name":"\u30102025 ASH\u3011\u4e9e\u76db\u91ab\u85e5\u8010\u7acb\u514b\u00ae\u591a\u9805\u7814\u7a76\u5165\u9078\uff0cPOLARIS-1\u7814\u7a76\u6578\u64da\u9996\u6b21\u767c\u5e03 - \u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","isPartOf":{"@id":"https:\/\/pingtungtimes.com.tw\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=378515#primaryimage"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=378515#primaryimage"},"thumbnailUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Ascentage_APAC_Logo-12.jpg","datePublished":"2025-11-04T01:22:00+00:00","description":"\u7f8e\u570b\u99ac\u88e1\u862d\u5dde\u7f85\u514b\u7dad\u723e\u5e02\u548c\u4e2d\u570b\u8607\u5dde2025\u5e7411\u67084\u65e5 \/\u7f8e\u901a\u793e\/ --\u00a0\u81f4\u529b\u65bc\u5728\u816b\u7624\u7b49\u9818\u57df\u958b\u767c\u5275\u65b0\u85e5\u7269\u7684\u9818\u5148\u7684\u751f\u7269\u91ab\u85e5\u4f01\u696d\u2014\u2014\u4e9e\u76db\u91ab\u85e5\uff08\u7d0d\u65af\u9054\u514b\u4ee3\u78bc\uff1aAAPG\uff1b\u9999\u6e2f\u806f\u4ea4\u6240\u4ee3\u78bc\uff1a6855\uff09\u5ba3\u5e03\uff0c\u516c\u53f8\u539f\u52751\u985e\u65b0\u85e5\u5967\u96f7\u5df4\u66ff\u5c3c\uff08\u5546\u54c1\u540d\uff1a\u8010\u7acb\u514b\u00ae\uff09\u6709\u591a\u9805\u81e8\u5e8a\u9032\u5c55\u7372\u9078\u7b2c67\u5c46\u7f8e\u570b\u8840\u6db2\u5b78\u6703\uff08American Society of Hematology\uff0cASH\uff09\u5e74\u6703\uff0c\u9019\u662f\u8a72\u54c1\u7a2e\u7684\u81e8\u5e8a\u9032\u5c55\u9023\u7e8c\u7b2c8\u5e74\u5165\u9078ASH\u5e74\u6703\u3002\u503c\u5f97\u4e00\u63d0\u7684\u662f\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u54c1\u7a2e\uff08\u8010\u7acb\u514b\u00ae\u3001\u5229\u751f\u59a5\u00ae\u3001APG-5918\uff09\u6709\u591a\u9805\u81e8\u5e8a\u548c\u81e8\u5e8a\u524d\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5176\u4e2d\u4e00\u9805\u7372\u53e3\u982d\u5831\u544a\u3002 \u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\u3002\u5176\u5728\u4e2d\u570b\u7684\u5546\u696d\u5316\u63a8\u5ee3\u7531\u4e9e\u76db\u91ab\u85e5\u548c\u4fe1\u9054\u751f\u7269\u5171\u540c\u8ca0\u8cac\u3002\u516c\u53f8\u5c07\u5728\u6b64\u6b21ASH\u5e74\u6703\u4e0a\uff0c\u9996\u6b21\u767c\u5e03\u8010\u7acb\u514b\u00ae\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684\u5168\u7403III\u671f\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff09\u6700\u65b0\u6578\u64da\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u6cbb\u7642\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5CML-CP\u60a3\u8005\u7684\u96a8\u6a5f\u5c0d\u7167\u6ce8\u518aII\u671f\u7814\u7a76\u76844\u5e74\u96a8\u8a2a\u6578\u64da\u3001\u548c\u5176\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCML-CP\u60a3\u8005\u7684\u6578\u64da\u4e5f\u5c07\u5728\u6b64\u6b21\u6703\u8b70\u4e0a\u66f4\u65b0\u3002 \u4e00\u5e74\u4e00\u5ea6\u7684ASH\u5e74\u6703\u662f\u5168\u7403\u8840\u6db2\u5b78\u9818\u57df\u898f\u6a21\u6700\u5927\u7684\u570b\u969b\u5b78\u8853\u76db\u6703\u4e4b\u4e00\uff0c\u5168\u9762\u6db5\u84cb\u4e86\u8840\u6db2\u75be\u75c5\u7684\u75c5\u56e0\u7814\u7a76\u548c\u6cbb\u7642\u7814\u7a76\u3002\u7b2c67\u5c46ASH\u5e74\u6703\u5c07\u65bc\u7576\u5730\u6642\u95932025\u5e7412\u67086\u65e5\u81f39\u65e5\u9593\u5728\u7f8e\u570b\u4f5b\u7f85\u88e1\u9054\u5dde\u5967\u862d\u591a\u5e02\u4ee5\u7dda\u4e0b\u7d50\u5408\u7dda\u4e0a\u7684\u5f62\u5f0f\u8209\u884c\u3002 \u4e9e\u76db\u91ab\u85e5\u9996\u5e2d\u91ab\u5b78\u5b98\u7fdf\u4e00\u5e06\u535a\u58eb\u8868\u793a\uff1a\u300c\u4eca\u5e74\u5c07\u662f\u8010\u7acb\u514b\u00ae\u9023\u7e8c\u7b2c8\u5e74\u5728ASH\u5e74\u6703\u4e0a\u5c55\u793a\u6700\u65b0\u81e8\u5e8a\u9032\u5c55\uff0c\u518d\u4e00\u6b21\u9ad4\u73fe\u4e86\u570b\u969b\u8840\u6db2\u5b78\u754c\u5c0d\u8010\u7acb\u514b\u00ae\u7684\u5de8\u5927\u8a8d\u53ef\u3002\u76ee\u524d\uff0c\u8a72\u54c1\u7a2e\u67093\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u3002\u6b64\u5916\uff0c\u4eca\u5e74\u516c\u53f83\u500b\u91cd\u9ede\u54c1\u7a2e\u6709\u591a\u9805\u9032\u5c55\u5165\u9078ASH\u5e74\u6703\u5c55\u793a\u53ca\u5831\u544a\uff0c\u5145\u5206\u986f\u73fe\u4e86\u516c\u53f8\u7684\u5168\u7403\u5275\u65b0\u548c\u958b\u767c\u5be6\u529b\u3002\u6211\u5011\u671f\u5f85\u5728\u5f8c\u7e8c\u6703\u8b70\u671f\u9593\u8207\u5927\u5bb6\u5206\u4eab\u76f8\u95dc\u7814\u7a76\u7684\u8a73\u5be6\u6578\u64da\u3002\u672a\u4f86\uff0c\u4e9e\u76db\u91ab\u85e5\u5c07\u9032\u4e00\u6b65\u52a0\u901f\u63a8\u9032\u81e8\u5e8a\u958b\u767c\uff0c\u65e9\u65e5\u70ba\u60a3\u8005\u5e36\u4f86\u66f4\u591a\u6cbb\u7642\u9078\u64c7\u3002\u300d ASH 2025\u4e9e\u76db\u91ab\u85e5\u7522\u54c1\u76f8\u95dc\u7814\u7a76\u4e00\u89bd\uff1a \u5c55\u793a\u5f62\u5f0f \u54c1\u7a2e \u6458\u8981\u6a19\u984c \u7de8\u865f \u53e3\u982d\u5831\u544a \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis) \u4e00\u9805\u95dc\u65bc\u5229\u6c99\u6258\u514b\u62c9\u55ae\u85e5\u6cbb\u7642\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08BTKi\uff09\u6cbb\u7642\u5931\u6557\u7684\u5fa9\u767c\/\u96e3\u6cbb\u6027\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/ \u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u7684\u6ce8\u518a\u6027II\u671f\u7814\u7a76\u7d50\u679c 88 \u58c1\u5831\u5c55\u793a \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 Results of the APG2575AU101 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax\u2013exposed myeloid malignancies \u5229\u6c99\u6258\u514b\u62c9\u806f\u5408\u963f\u624e\u80de\u7518\u6cbb\u7642\u521d\u6cbb\u6216\u65e2\u5f80\u4f7f\u7528\u904e\u7dad\u5948\u6258\u514b\u7684\u9ad3\u7cfb\u816b\u7624\u7684\u81e8\u5e8a\u7814\u7a76\uff08APG2575AU101\uff09\u7d50\u679c 1641 \u5967\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Results of POLARIS-1, a global phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) \u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684 \u5168\u7403III\u671f\u7814\u7a76POLARIS-1\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c 1574 Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations \u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u60272\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08CML-CP\uff09\uff0c \u5305\u62ec\u7121T315I\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08BAT\uff09\uff1a4\u5e74\u96a8\u8a2a\u671f 3788 Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML) \u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u6578\u64da 3782 Preclinical and clinical Study of olverembatinib in patients with myeloid\/lymphoid neoplasms with FGFR1 rearrangement \u5967\u96f7\u5df4\u66ff\u5c3c\u7684\u81e8\u5e8a\u524d\u8207\u81e8\u5e8a\u7814\u7a76\uff1a\u6cbb\u7642\u4f34FGFR1\u91cd\u6392\u7684\u9ad3\u7cfb\/\u6dcb\u5df4\u816b\u7624 1979 Olverembatinib-mediated deep remission improves allogeneic stem cell transplantation outcome in patients with blast crisis chronic myeloid leukemia: First real-world practice report \u5967\u96f7\u5df4\u66ff\u5c3c\u4ecb\u5c0e\u7684\u6df1\u5ea6\u7de9\u89e3\u63d0\u5347\u7570\u57fa\u56e0\u5e72\u7d30\u80de\u79fb\u690d\u5728\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u6025\u8b8a\u671f\u60a3\u8005\u4e2d\u7684\u7642\u6548\uff1a \u9996\u4efd\u771f\u5be6\u4e16\u754c\u5be6\u8e10\u5831\u544a 1999 The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, control trial \u5c0d\u65bc\u65e2\u5f80\u63a5\u53d7\u904e\u81f3\u5c11\u5169\u7a2eTKI\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u6027\u767d\u8840\u75c5\u6162\u6027\u671f\u60a3\u8005\uff0c\u63db\u7528\u5967\u96f7\u5df4\u66ff\u5c3c\u8207\u7e7c\u7e8c\u539fTKI\u6cbb\u7642\u7684\u7642\u6548\u8207\u5b89\u5168\u6027\uff1a \u4e00\u9805\u524d\u77bb\u6027\u3001\u591a\u4e2d\u5fc3\u3001\u5c0d\u7167\u7814\u7a76 3779 Clinical and molecular features associated with glucolipid metabolic disorders and cardio-\/cerebro-vascular adverse events in CML patients receiving olverembatinib therapy \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\u60a3\u8005\u51fa\u73fe\u7cd6\u8102\u4ee3\u8b1d\u7d0a\u4e82\u53ca\u5fc3\/\u8166\u8840\u7ba1\u4e0d\u826f\u4e8b\u4ef6\u7684 \u81e8\u5e8a\u8207\u5206\u5b50\u7279\u5f81 5561 APG-5918 Embryonic ectoderm development (EED) inhibitor APG-5918 overcomes immunomodulatory drug (IMiD) resistance as monotherapy and synergizes with IMiDs\/cereblon E3 ligase modulators (CELMoDs) in preclinical models of multiple myeloma (MM) \u80da\u80ce\u5916\u80da\u5c64\u767c\u80b2\uff08EED\uff09\u6291\u5236\u5291APG-5918\u55ae\u85e5\u5728\u591a\u767c\u6027\u9aa8\u9ad3\u7624\uff08MM\uff09\u81e8\u5e8a\u524d\u6a21\u578b\u4e2d\u514b\u670d\u4e86\u514d\u75ab\u8abf\u7bc0\u85e5\u7269\uff08IMiD\uff09\u8010\u85e5\u6027\u4e26\u986f\u793a\u4e86 \u8207IMiDs\/Cereblon E3\u9023\u63a5\u9176\u8abf\u7bc0\u5291\uff08CELMoDs\uff09\u7684\u5354\u540c\u6548\u61c9 1528 \u5728\u7dda\u767c\u5e03 \u5967\u96f7\u5df4\u66ff\u5c3c \uff08HQP1351\uff09 Single CAR-t infusion during front-line consolidation induces deep and sustained remissionin newly diagnosed adult ph+b- ALL: A prospective phase 2 study \u5c0d\u65bc\u65b0\u8a3a\u65b7\u7684\u6210\u4ebaPh\u967d\u6027B-ALL\u60a3\u8005\uff0c\u5728\u4e00\u7dda\u978f\u56fa\u6cbb\u7642\u968e\u6bb5\u9032\u884c\u55ae\u6b21CAR-T\u7d30\u80de\u8f38\u6ce8\uff0c\u53ef\u8a98\u5c0e\u6df1\u5ea6\u4e14\u6301\u4e45\u7684\u7de9\u89e3\uff1a\u4e00\u9805\u524d\u77bb\u6027II\u671f\u7814\u7a76\u3002 442 \u5229\u6c99\u6258\u514b\u62c9 \uff08APG-2575\uff09 BCL-2 inhibition in North American adult T-cell leukemia\/lymphoma: Preclinical insightsand early clinical outcomes BCL-2\u6291\u5236\u5291\u5728\u5317\u7f8e\u6210\u4ebaT\u7d30\u80de\u767d\u8840\u75c5\/\u6dcb\u5df4\u7624\u4e2d\u7684\u9776\u5411\u6cbb\u7642\uff1a\u81e8\u5e8a\u524d\u7814\u7a76\u8207\u65e9\u671f\u81e8\u5e8a\u7d50\u679c 3304 \u5967\u96f7\u5df4\u66ff\u5c3c\u5165\u90782025 ASH\u5e74\u6703\u7684\u4e3b\u8981\u7814\u7a76\u6458\u8981\u5982\u4e0b\uff1a\uff08\u5229\u6c99\u6258\u514b\u62c9\u5165\u9078ASH\u5e74\u6703\u7684\u6458\u8981\u8a73\u7d30\u4fe1\u606f\u53c3\u898b\u540c\u671f\u767c\u5e03\u7684\u53e6\u4e00\u7bc7\u65b0\u805e\u7a3f\uff09 Results of POLARIS-1, a global Phase 3 study (Part A): olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)\u4e00\u9805\u95dc\u65bc\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u6cbb\u7642\u521d\u6cbb\uff08ND\uff09\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\uff08Ph+\uff09\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08ALL\uff09\u60a3\u8005\u7684\u5168\u7403III\u671f\u7814\u7a76POLARIS-1\uff08\u7b2c\u4e00\u968e\u6bb5\uff09\u7d50\u679c\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a1574\u5206\u6703\u5834\uff1a613. \u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff1a\u540c\u7a2e\u79fb\u690d\u4ee5\u5916\u7684\u7642\u6cd5\uff1a\u58c1\u5831\u5c55\u793aI\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67086\u65e5\uff0c\u661f\u671f\u516d\uff0c\u4e0b\u534817:30 \u2013 19:30\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0a\u53486:30 \u2013 8:30\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388\u5831\u544a\u4eba\uff1a\u8607\u5dde\u5927\u5b78\u9644\u5c6c\u7b2c\u4e00\u91ab\u9662 \u9673\u8607\u5be7\u6559\u6388\u6838\u5fc3\u8981\u9ede\uff1a\u8a72\u7814\u7a76\uff08POLARIS-1\u7814\u7a76\uff1bNCT06051409\uff09\u70ba\u4e00\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5f37\u5ea6\u5316\u7642\u5728\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5fae\u5c0f\u6b98\u7559\u75c5\uff08MRD\uff1b\u9006\u8f49\u9304qPCR\u65b9\u6cd5\u6aa2\u6e2cBCR-ABL1\/ABL1\u22640.01%\uff09\u9670\u6027\u7387\u3002 \u7642\u6548\u6578\u64da\uff1a \u622a\u81f32025\u5e747\u670818\u65e5\uff0c\u572853\u4f8b\u53ef\u8a55\u4f30\u7642\u6548\u7684\u60a3\u8005\u4e2d\uff0c50\u4f8b\u60a3\u8005\uff0894.3%\uff09\u5728\u8a98\u5c0e\u6cbb\u76423\u500b\u5468\u671f\u5167\u5be6\u73fe\u4e86\u5b8c\u5168\u7de9\u89e3\uff08CR\uff09\u6216CR\u4f34\u4e0d\u5b8c\u5168\u8840\u6db2\u5b78\u6062\u5fa9\uff0c\u6700\u4f73MRD\u9670\u6027\u7387\u548cMRD\u9670\u6027CR\u7387\u5206\u5225\u70ba66.0%\u548c64.2%\u3002 IKZF1plus\uff08\u5c24\u5176\u5408\u4e26BTG1\u7f3a\u5931\uff09\u662fB-ALL\u516c\u8a8d\u7684\u9ad8\u5371\u56e0\u7d20\uff0c\u5e38\u5c0e\u81f4\u5316\u7642\u8010\u85e5\u8207\u9ad8\u5fa9\u767c\u3002\u5728\u672c\u7814\u7a7610\u4f8b\u651c\u5e36\u6b64\u7279\u5f81\u7684\u60a3\u8005\u4e2d\uff0c\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642\u7684\u5206\u5b50\u5b78\u7de9\u89e3\u7387\u9ad8\u905490%\uff089\/10\uff09\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u4f4e\u5291\u91cf\u5316\u7642\u8010\u53d7\u6027\u826f\u597d\u3002\u5e38\u898b\u7684\uff08\u767c\u751f\u7387>15%\uff093\u7d1a\u6216\u4ee5\u4e0a\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u4e0d\u826f\u4e8b\u4ef6\uff08TEAEs\uff09\u70ba\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\u75c7\uff0863.6%\uff09\u3001\u8840\u5c0f\u677f\u6e1b\u5c11\u75c7\uff0856.4%\uff09\u3001\u767d\u7d30\u80de\u6e1b\u5c11\u75c7\uff0854.5%\uff09\u3001\u8ca7\u8840\uff0849.1%\uff09\u3001\u80ba\u708e\uff0830.9%\uff09\u3001\u4f4e\u9240\u8840\u75c7\uff0820%\uff09\u548c\u809d\u529f\u80fd\u7570\u5e38\uff0816.4%\uff09\u3002 \u7d50\u8ad6\uff1a\u5728\u63a5\u53d7\u5967\u96f7\u5df4\u66ff\u5c3c\u806f\u5408\u5316\u7642\u6cbb\u7642\u7684\u521d\u6cbbPh+ ALL\u60a3\u8005\u4e2d\uff0c\u81f3\u8a98\u5c0e\u6cbb\u7642\u7d50\u675f\u6642MRD\u9670\u6027CR\u7387\u905464.2%\uff0c\u4e26\u986f\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\u3002 Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-phase chronic myeloid leukemia (CML-CP) in a registrational randomized phase 2 trial: up to 4-year follow-up including patients without T315I mutations\u5728\u4e00\u9805\u96a8\u6a5f\u3001\u6ce8\u518a\u60272\u671f\u81e8\u5e8a\u8a66\u9a57\u4e2d\u5967\u96f7\u5df4\u66ff\u5c3c\uff08HQP1351\uff09\u5c0d\u916a\u6c28\u9178\u6fc0\u9176\u6291\u5236\u5291\uff08TKI\uff09\u8010\u85e5\u7684\u6162\u6027\u671f\u6162\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08CML-CP\uff09\uff0c\u5305\u62ec\u7121T315I\u7a81\u8b8a\u60a3\u8005\u7684\u6cbb\u7642\u7642\u6548\u512a\u65bc\u73fe\u6709\u6700\u4f73\u6cbb\u7642\u65b9\u6848\uff08BAT\uff09\uff1a4\u5e74\u96a8\u8a2a\u671f\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a3788\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 \u2013 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e7412\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 \u2013 9:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388\u5831\u544a\u4eba\uff1a\u5317\u4eac\u5927\u5b78\u8840\u6db2\u75c5\u7814\u7a76\u6240\u3001\u5317\u4eac\u5927\u5b78\u4eba\u6c11\u91ab\u9662\uff0c\u6c5f\u5029\u6559\u6388Highlights:\u6838\u5fc3\u8981\u9ede\uff1a \u8a72\u7814\u7a76\uff08NCT04126681\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u96a8\u6a5f\u5c0d\u7167\u3001\u591a\u4e2d\u5fc3\u7684\u95dc\u9375\u6ce8\u518aII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u672c\u5831\u544a\u70ba\u4e00\u98052023ASH\u5e74\u6703\u53e3\u982d\u5831\u544a\u7684\u7814\u7a76\u66f4\u65b0\u6578\u64da\u3002\u622a\u81f32025\u5e741\u670813\u65e5\uff0c\u5171\u6709144\u4f8bCML-CP\u60a3\u8005\u5165\u7d44\uff0c\u5176\u4e2d105\u4f8b\u70ba\u4e0d\u4f34T315I\u7a81\u8b8a\u60a3\u8005\u3002 \u5728\u672c\u7814\u7a76\u4e2d\uff0c\u60a3\u8005\u88ab\u6309\u71672:1 \u6bd4\u4f8b\u96a8\u6a5f\u5206\u7d44\u9032\u5165\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548c\u7814\u7a76\u8005\u6c7a\u5b9a\u7684\u73fe\u6709\u6700\u4f73\u6cbb\u7642\uff08BAT\uff09\u5c0d\u7167\u7d44\u3002\u4e3b\u8981\u7d42\u9ede\u70ba\u7121\u4e8b\u4ef6\u751f\u5b58\u671f\uff08EFS\uff09\u3002 \u7642\u6548\u6578\u64da\uff1a \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u986f\u8457\u9577\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CMP-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba21.22\u500b\u6708\u548c2.86\u500b\u6708\uff08P < 0.001\uff09\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u4e2d\u4f4dEFS\u5206\u5225\u70ba11.96 \u548c3.14\u500b\u6708\uff08P = 0.0159\uff09\u3002 \u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u7684\u5176\u4ed6\u7642\u6548\u6307\u6a19\u986f\u8457\u9ad8\u65bcBAT\u6cbb\u7642\u7d44\uff1a\u5728\u6240\u6709CML-CP\u60a3\u8005\u4e2d\uff0c\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u7684\u5b8c\u5168\u8840\u6db2\u5b78\u7de9\u89e3(CHR)\u7387\u5206\u5225\u70ba85% \u548c34.8%\uff0c\u5b8c\u5168\u7d30\u80de\u907a\u50b3\u5b78\u53cd\u61c9\uff08CCyR\uff09\u7387\u5206\u5225\u70ba37.5%\u548c18.9%\uff0c\u4e3b\u8981\u5206\u5b50\u5b78\u53cd\u61c9\uff08MMR\uff09\u7387\u5206\u5225\u70ba29.5%\u548c8.1%\uff1b\u5728\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u4e2d\uff0cCHR\u5206\u5225\u70ba82.1% \u548c50.0%\uff0cCCyR\u5206\u5225\u70ba25.8%\u548c20.7%\uff0cMMR\u5206\u5225\u70ba16.1%\u548c 10.3%\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u6cbb\u7642\u7d44\u548cBAT\u6cbb\u7642\u7d44\u5728\u4f34\u6216\u4e0d\u4f34T315I\u7a81\u8b8a\u7684CML-CP\u60a3\u8005\u4e2d\u5747\u5c55\u793a\u51fa\u826f\u597d\u7684\u5b89\u5168\u6027\uff0c\u4e3b\u8981\u4e0d\u826f\u4e8b\u4ef6\u70ba\u8840\u6db2\u5b78\u6bd2\u6027\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u6cbb\u7642\u5c0d\u4e00\u4ee3\u548c\u4e8c\u4ee3TKI\u5747\u8010\u85e5\u548c\/\u6216\u4e0d\u8010\u53d7\u7684CML-CP\u53d7\u8a66\u8005\uff0c\u5305\u62ec\u4e0d\u4f34T315I\u7a81\u8b8aCML-CP\u60a3\u8005\u6642\uff0c\u8f03BAT\u6cbb\u7642\u7d44\u5c55\u793a\u51fa\u660e\u986f\u6cbb\u7642\u512a\u52e2\u3002 Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic phase-chronic myeloid leukemia (CP-CML)\u66f4\u65b0\u5967\u96f7\u5df4\u66ff\u5c3c\u4e8c\u7dda\u6cbb\u7642CP-CML\u60a3\u8005\u6578\u64da\u5c55\u793a\u5f62\u5f0f\uff1a\u58c1\u5831\u5c55\u793a\u6458\u8981\u7de8\u865f\uff1a3782\u5206\u6703\u5834\uff1a632. \u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\uff1a\u81e8\u5e8a\u53ca\u6d41\u884c\u75c5\u5b78\u7814\u7a76\uff1a\u58c1\u5831\u5c55\u793aII\u5831\u544a\u6642\u9593\uff1a2025\u5e7412\u67087\u65e5\uff0c\u661f\u671f\u65e5\uff0c\u4e0b\u534818:00 - 20:00\uff08\u7f8e\u570b\u6771\u90e8\u6642\u9593\uff092025\u5e74 12\u67088\u65e5\uff0c\u661f\u671f\u4e00\uff0c\u4e0a\u53487:00 - 9:00\uff08\u5317\u4eac\u6642\u9593\uff09\u7b2c\u4e00\u4f5c\u8005\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388\u5831\u544a\u4eba\uff1a\u6b66\u6f22\u5354\u548c\u91ab\u9662 \u9ece\u7def\u660e\u6559\u6388\u6838\u5fc3\u8981\u9ede\uff1a\u8a72\u7814\u7a76\uff08ChiCTR2200061655\uff09\u662f\u4e00\u9805\u958b\u653e\u6027\u3001\u55ae\u81c2\u3001\u591a\u4e2d\u5fc3\u81e8\u5e8a\u7814\u7a76\uff0c\u65e8\u5728\u8a55\u4f30\u9694\u65e5\u53e3\u670d40mg\u5967\u96f7\u5df4\u66ff\u5c3c\u5728\u65e2\u5f80\u4f7f\u7528\u904e\u4e00\u7a2eTKI\u6cbb\u7642\u5f8c\u8010\u85e5\u6216\u4e0d\u8010\u53d7\uff08\u5305\u62ec\u4f0a\u99ac\u66ff\u5c3c\u3001\u6c1f\u99ac\u66ff\u5c3c\u3001\u5c3c\u6d1b\u66ff\u5c3c\u53ca\u9054\u6c99\u66ff\u5c3c\u7b49\uff09\u7684\u975eT315I\u7a81\u8b8aCP-CML\u60a3\u8005\u4e2d\u7684\u7642\u6548\u548c\u5b89\u5168\u6027\u3002\u622a\u81f32025\u5e747\u670824\u65e5\uff0c\u5171\u5165\u7d44\u975eT315I \u7a81\u8b8a\u7684CP-CML \u60a3\u800547\u4f8b\u3002 \u7642\u6548\u6578\u64da\uff1a \u622a\u81f32025\u5e747\u670824\u65e5\uff0c39\u4f8b\uff0883.0%\uff09\u60a3\u8005\u63a5\u53d7\u4e86\u81f3\u5c111\u6b21\u7642\u6548\u8a55\u4f30\uff0c36\u4f8b\uff0876.6%\uff09\u63a5\u53d7\u4e86\u81f3\u5c112\u6b21\u7642\u6548\u8a55\u4f30\uff0c34\u4f8b\uff0872.3%\uff09\u63a5\u53d7\u4e86\u81f3\u5c113\u6b21\u7642\u6548\u8a55\u4f30\u30022\u4f8b\u60a3\u8005\u5c1a\u672a\u9032\u884c\u9996\u6b21\u7642\u6548\u8a55\u4f30\u3002 \u81f3\u622a\u6b62\u65e5\u671f\uff0c71.8%\uff0828\/39\uff09\u7684\u60a3\u8005\u7372CCyR\uff0c43.6%\uff0817\/39\uff09\u7372MMR\u3002\u7b2c6\u30019\u300112\u300115\u300118\u300121\u300124\u500b\u5468\u671f\u8a55\u4f30\u7684CCyR\u7387\u548cMMR\u7387\u5206\u5225\u70ba54.3%\u548c25.7%\u300166.7%\u548c33.3%\u300174.2%\u548c35.5%\u300184.6%\u548c46.2%\u300185.7% \u548c 47.6%\u300190.0% \u548c 60.0%\u300189.5% \u548c 57.9%\u3002\u63d0\u793a\u7642\u6548\u96a8\u7528\u85e5\u6642\u9593\u5ef6\u9577\u800c\u7de9\u89e3\u9010\u6f38\u52a0\u6df1\u3002 \u572839\u4f8b\u7642\u6548\u53ef\u8a55\u4f30\u7684\u60a3\u8005\u4e2d\uff0c\u670930\u4f8b\u60a3\u8005\u65e2\u5f80\u4ee5\u4e8c\u4ee3TKI\u4f5c\u70ba\u4e00\u7dda\u6cbb\u7642\uff0c\u5176\u4e2d76.7%\uff0823\/30\uff09\u7372\u5f97CCyR\uff0c43.3%\uff0813\/30\uff09\u7372\u5f97MMR\uff1b\u5728\u65e2\u5f80\u63a5\u53d7\u4f0a\u99ac\u66ff\u5c3c\u6cbb\u7642\u76849\u4f8b\u60a3\u8005\u4e2d\uff0c55.6%\uff085\/9\uff09\u7372\u5f97CCyR\uff0c44.4%\uff084\/9\uff09\u7372\u5f97MMR\u3002 \u5b89\u5168\u6027\u6578\u64da\uff1a\u4e2d\u4f4d\uff08\u5340\u9593\uff09\u6cbb\u7642\u6642\u959316.0\uff081-18\uff09\u500b\u6708\u3002\u5171\u670942\u4f8b\uff0889.4%\uff09\u60a3\u8005\u767c\u751f\u4e86\u4efb\u4f55\u7d1a\u5225\u7684\u6cbb\u7642\u76f8\u95dc\u4e0d\u826f\u4e8b\u4ef6\uff08TRAEs\uff09\uff0c\u5176\u4e2d21\u4f8b\uff0844.7%\uff09\u767c\u751f\u4e86\u22653\u7d1aTRAEs\uff0c6\u4f8b\uff0812.8%\uff09\u767c\u751f\u4e86\u8207\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dc\u7684\u56b4\u91cd\u4e0d\u826f\u4e8b\u4ef6\uff08SAEs\uff09\u3002\u22653\u7d1a\u8840\u6db2\u5b78\u4e0d\u826f\u53cd\u61c9\u5305\u62ec\u8840\u5c0f\u677f\u6e1b\u5c11\uff0842.6%\uff09\u3001\u4e2d\u6027\u7c92\u7d30\u80de\u6e1b\u5c11\uff0825.5%\uff09\u548c\u8ca7\u8840\uff088.5%\uff09\u3002\u5967\u96f7\u5df4\u66ff\u5c3c\u76f8\u95dcSAEs\u5305\u62ec\u8840\u5c0f\u677f\u8a08\u6578\u6e1b\u5c11\uff086.4%\uff09\u3001\u8ca7\u8840\u3001\u9aa8\u9ad3\u6291\u5236\u548c\u767c\u71b1\uff08\u54042.1%\uff09\u3002\u7121\u6b7b\u4ea1\u5831\u544a\u3002 \u7d50\u8ad6\uff1a\u5967\u96f7\u5df4\u66ff\u5c3c\u53ef\u80fd\u70ba\u4e8c\u7ddaCP-CML\u60a3\u8005\u63d0\u4f9b\u4e00\u7a2e\u5b89\u5168\u6709\u6548\u7684\u6cbb\u7642\u9078\u64c7\uff0c\u5c24\u5176\u662f\u5c0d\u65bc\u4e00\u7dda\u4f7f\u7528\u4e8c\u4ee3\u00a0TKIs\u6cbb\u7642\u5931\u6557\u7684\u60a3\u8005\u3002 \u95dc\u65bc\u4e9e\u76db\u91ab\u85e5 \u4e9e\u76db\u91ab\u85e5\u662f\u4e00\u5bb6\u7d9c\u5408\u6027\u7684\u5168\u7403\u751f\u7269\u91ab\u85e5\u4f01\u696d\uff0c\u81f4\u529b\u65bc\u7814\u767c\u5275\u65b0\u85e5\uff0c\u4ee5\u89e3\u6c7a\u816b\u7624\u7b49\u9818\u57df\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u30022019\u5e7410\u670828\u65e5\uff0c\u516c\u53f8\u5728\u9999\u6e2f\u806f\u4ea4\u6240\u4e3b\u677f\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1a6855.HK\uff1b2025\u5e741\u670824\u65e5\uff0c\u516c\u53f8\u5728\u7f8e\u570b\u7d0d\u65af\u9054\u514b\u8b49\u5238\u4ea4\u6613\u6240\u639b\u724c\u4e0a\u5e02\uff0c\u80a1\u7968\u4ee3\u78bc\uff1aAAPG\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5efa\u7acb\u8c50\u5bcc\u7684\u5275\u65b0\u85e5\u7522\u54c1\u7ba1\u7dda\uff0c\u5305\u62ec\u6291\u5236Bcl-2\u548c\u00a0MDM2-p53 \u7b49\u7d30\u80de\u51cb\u4ea1\u901a\u8def\u95dc\u9375\u86cb\u767d\u7684\u6291\u5236\u5291\uff1b\u65b0\u4e00\u4ee3\u91dd\u5c0d\u764c\u75c7\u6cbb\u7642\u4e2d\u51fa\u73fe\u7684\u6fc0\u9176\u7a81\u8b8a\u9ad4\u7684\u6291\u5236\u5291\u7b49\u3002 \u516c\u53f8\u6838\u5fc3\u54c1\u7a2e\u8010\u7acb\u514b\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u7b2c\u4e09\u4ee3BCR-ABL\u6291\u5236\u5291\uff0c\u4e14\u7372\u6279\u9069\u61c9\u75c7\u5747\u88ab\u6210\u529f\u7d0d\u5165\u570b\u5bb6\u91ab\u4fdd\u85e5\u54c1\u76ee\u9304\uff0c\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u8010\u7acb\u514b\u00ae\u4e00\u9805\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff08POLARIS-2\uff09\uff0c\u7528\u65bc\u6cbb\u7642\u65e2\u5f80\u63a5\u53d7\u904e\u6cbb\u7642\u7684\u6162\u6027\u9ad3\u7d30\u80de\u767d\u8840\u75c5\u6162\u6027\u671f\uff08CML-CP\uff09\u6210\u5e74\u60a3\u8005\u3002\u6b64\u5916\uff0c\u8010\u7acb\u514b\u00ae\u806f\u5408\u6cbb\u7642\u65b0\u8a3a\u65b7\u8cbb\u57ce\u67d3\u8272\u9ad4\u967d\u6027\u6025\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\uff08Ph+ ALL\uff09\u60a3\u8005\u548c\u6cbb\u7642\u7425\u73c0\u9178\u812b\u6c2b\u9176\uff08SDH\uff09\u7f3a\u9677\u578b\u80c3\u8178\u9053\u9593\u8cea\u7624\uff08GIST\uff09\u60a3\u8005\u7684\u5168\u7403\u6ce8\u518aIII\u671f\u7814\u7a76\u6b63\u5728\u958b\u5c55\u4e2d\u3002 \u516c\u53f8\u53e6\u4e00\u91cd\u78c5\u54c1\u7a2e\u5229\u751f\u59a5\u00ae\u662f\u4e2d\u570b\u9996\u500b\u7372\u6279\u4e0a\u5e02\u7684\u570b\u7522\u539f\u5275Bcl-2\u6291\u5236\u5291\uff0c\u5df2\u7372\u6279\u7528\u65bc\u65e2\u5f80\u7d93\u904e\u81f3\u5c11\u5305\u542b\u5e03\u9b6f\u9813\u916a\u6c28\u9178\u6fc0\u9176\uff08BTK\uff09\u6291\u5236\u5291\u5728\u5167\u7684\u4e00\u7a2e\u7cfb\u7d71\u6cbb\u7642\u7684\u6210\u4eba\u6162\u6027\u6dcb\u5df4\u7d30\u80de\u767d\u8840\u75c5\/\u5c0f\u6dcb\u5df4\u7d30\u80de\u6dcb\u5df4\u7624\uff08CLL\/SLL\uff09\u60a3\u8005\u3002\u76ee\u524d\uff0c\u4e9e\u76db\u91ab\u85e5\u6b63\u5728\u958b\u5c55\u5229\u751f\u59a5\u00ae\u56db\u9805\u5168\u7403\u6ce8\u518aIII\u671f\u81e8\u5e8a\u7814\u7a76\uff0c\u5206\u5225\u70ba\u7372\u7f8e\u570bFDA\u8a31\u53ef\u7684\u6cbb\u7642\u7d93\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA\u7814\u7a76\uff1b\u6cbb\u7642\u521d\u6cbbCLL\/SLL\u60a3\u8005\u7684GLORA-2\u7814\u7a76\uff1b\u6cbb\u7642\u65b0\u8a3a\u65b7\u8001\u5e74\u6216\u9ad4\u5f31\u6025\u6027\u9ad3\u7cfb\u767d\u8840\u75c5\uff08AML\uff09\u7684GLORA-3\u7814\u7a76\uff1b\u4ee5\u53ca\u7372\u7f8e\u570bFDA\u3001\u6b50\u6d32EMA\u8207\u4e2d\u570bCDE\u540c\u6b65\u6279\u51c6\u958b\u5c55\u7684\u6cbb\u7642\u65b0\u8a3a\u65b7\u4e2d\u9ad8\u5371\u9aa8\u9ad3\u589e\u751f\u7570\u5e38\u7d9c\u5408\u5f81\uff08MDS\uff09\u60a3\u8005\u7684GLORA-4\u7814\u7a76\u3002 \u622a\u81f3\u76ee\u524d\uff0c\u516c\u53f84\u500b\u5728\u7814\u65b0\u85e5\u5171\u737216\u9805FDA\u548c1\u9805\u6b50\u76df\u5b64\u5152\u85e5\u8cc7\u683c\u8a8d\u5b9a\uff0c2\u9805FDA\u5feb\u901f\u901a\u9053\u8cc7\u683c\u4ee5\u53ca2\u9805FDA\u5152\u7ae5\u7f55\u898b\u75c5\u8cc7\u683c\u8a8d\u8b49\u3002\u6191\u501f\u5f37\u5927\u7684\u7814\u767c\u80fd\u529b\uff0c\u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u5168\u7403\u8303\u570d\u5167\u9032\u884c\u77e5\u8b58\u7522\u6b0a\u5e03\u5c40\uff0c\u4e26\u8207\u6b66\u7530\u3001\u9ed8\u6c99\u6771\u3001\u963f\u65af\u5229\u5eb7\u3001\u8f1d\u745e\u3001\u4fe1\u9054\u7b49\u9818\u5148\u7684\u751f\u7269\u5236\u85e5\u516c\u53f8\uff0c\u4ee5\u53ca\u6885\u5967\u91ab\u5b78\u4e2d\u5fc3\uff08Mayo Clinic\uff09\u3001\u4e39\u5a1c\u6cd5\u4f2f\u764c\u75c7\u7814\u7a76\u9662\uff08Dana-Farber Cancer Institute\uff09\u3001\u7f8e\u570b\u570b\u5bb6\u764c\u75c7\u7814\u7a76\u6240\uff08NCI\uff09\u548c\u5bc6\u897f\u6839\u5927\u5b78\u7b49\u5b78\u8853\u6a5f\u69cb\u9054\u6210\u5168\u7403\u5408\u4f5c\u95dc\u7cfb\u3002 \u4e9e\u76db\u91ab\u85e5\u5df2\u5728\u539f\u5275\u65b0\u85e5\u7814\u767c\u8207\u81e8\u5e8a\u958b\u767c\u9818\u57df\u5efa\u7acb\u7d93\u9a57\u8c50\u5bcc\u7684\u570b\u969b\u5316\u4eba\u624d\u5718\u968a\uff0c\u4ee5\u53ca\u6210\u719f\u7684\u5546\u696d\u5316\u751f\u7522\u8207\u5e02\u5834\u71df\u92b7\u5718\u968a\u3002\u4e9e\u76db\u91ab\u85e5\u5c07\u4e0d\u65b7\u63d0\u9ad8\u7814\u767c\u80fd\u529b\uff0c\u52a0\u901f\u63a8\u9032\u516c\u53f8\u7522\u54c1\u7ba1\u7dda\u7684\u81e8\u5e8a\u958b\u767c\u9032\u5ea6\uff0c\u771f\u6b63\u8e10\u884c\u300c\u89e3\u6c7a\u4e2d\u570b\u4e43\u81f3\u5168\u7403\u60a3\u8005\u5c1a\u672a\u6eff\u8db3\u7684\u81e8\u5e8a\u9700\u6c42\u300d\u7684\u4f7f\u547d\uff0c\u4ee5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002 \u524d\u77bb\u6027\u8072\u660e \u672c\u65b0\u805e\u7a3f\u5305\u542b\u6839\u64da\u7f8e\u570b\u300a1995\u5e74\u79c1\u4eba\u8b49\u5238\u8a34\u8a1f\u6539\u9769\u6cd5\u6848\u300b\uff0c\u4ee5\u53ca\u7d93\u4fee\u8a02\u7684\u300a1933\u5e74\u8b49\u5238\u6cd5\u300b\u7b2c27A\u689d\u548c\u300a1934\u5e74\u8b49\u5238\u4ea4\u6613\u6cd5\u300b\u7b2c21E\u689d\u6240\u754c\u5b9a\u7684\u524d\u77bb\u6027\u9673\u8ff0\u3002\u9664\u6b77\u53f2\u4e8b\u5be6\u9673\u8ff0\u5916\uff0c\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u6240\u6709\u5167\u5bb9\u5747\u53ef\u80fd\u69cb\u6210\u524d\u77bb\u6027\u9673\u8ff0\uff0c\u5305\u62ec\u4e9e\u76db\u91ab\u85e5\u5c0d\u672a\u4f86\u4e8b\u4ef6\u3001\u7d93\u71df\u6210\u679c\u6216\u8ca1\u52d9\u72c0\u6cc1\u6240\u767c\u8868\u7684\u610f\u898b\u3001\u9810\u671f\u3001\u4fe1\u5ff5\u3001\u8a08\u5283\u3001\u76ee\u6a19\u3001\u5047\u8a2d\u6216\u9810\u6e2c\u3002 \u9019\u4e9b\u524d\u77bb\u6027\u9673\u8ff0\u53d7\u5230\u8af8\u591a\u98a8\u96aa\u548c\u4e0d\u78ba\u5b9a\u6027\u7684\u5f71\u97ff\uff0c\u5177\u9ad4\u5167\u5bb9\u5df2\u5728\u4e9e\u76db\u91ab\u85e5\u5411\u7f8e\u570b\u8b49\u5238\u4ea4\u6613\u59d4\u54e1\u6703\uff08SEC\uff09\u63d0\u4ea4\u7684\u6587\u4ef6\u4e2d\u8a73\u7d30\u8aaa\u660e\uff0c\u5305\u62ec2025\u5e741\u670821\u65e5\u63d0\u4ea4\u7684\u7d93\u4fee\u8a02\u7684F-1\u8868\u683c\u6ce8\u518a\u8aaa\u660e\u66f8\u548c2025\u5e744\u670816\u65e5\u63d0\u4ea4\u768420-F\u8868\u683c\u4e2d\u7684\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u548c\u300c\u95dc\u65bc\u524d\u77bb\u6027\u9673\u8ff0\u53ca\u884c\u696d\u6578\u64da\u7684\u7279\u5225\u8aaa\u660e\u300d\u7ae0\u7bc0\u30012019\u5e7410\u670816\u65e5\u63d0\u4ea4\u7684\u9996\u6b21\u767c\u884c\u4e0a\u5e02\u62db\u80a1\u66f8\u4e2d\u7684\u300c\u524d\u77bb\u6027\u8072\u660e\u300d\u3001\u300c\u98a8\u96aa\u56e0\u7d20\u300d\u7ae0\u7bc0\uff0c\u4ee5\u53ca\u6211\u5011\u4e0d\u6642\u5411SEC\u6216HKEX\u63d0\u4ea4\u7684\u5176\u4ed6\u6587\u4ef6\u3002\u9019\u4e9b\u56e0\u7d20\u53ef\u80fd\u5c0e\u81f4\u5be6\u969b\u696d\u7e3e\u3001\u904b\u71df\u6c34\u5e73\u3001\u7d93\u71df\u6210\u679c\u6216\u6210\u5c31\u8207\u524d\u77bb\u6027\u9673\u8ff0\u4e2d\u660e\u793a\u6216\u6697\u793a\u7684\u4fe1\u606f\u5b58\u5728\u91cd\u5927\u5dee\u7570\u3002\u672c\u524d\u77bb\u6027\u8072\u660e\u4e2d\u7684\u9673\u8ff0\u4e0d\u69cb\u6210\u516c\u53f8\u7ba1\u7406\u5c64\u7684\u5229\u6f64\u9810\u6e2c\u3002 \u56e0\u6b64\uff0c\u8a72\u7b49\u524d\u77bb\u6027\u9673\u8ff0\u4e0d\u61c9\u88ab\u8996\u70ba\u5c0d\u672a\u4f86\u4e8b\u4ef6\u7684\u9810\u6e2c\u3002\u672c\u65b0\u805e\u7a3f\u4e2d\u7684\u524d\u77bb\u6027\u9673\u8ff0\u50c5\u57fa\u65bc\u4e9e\u76db\u91ab\u85e5\u7576\u524d\u5c0d\u672a\u4f86\u767c\u5c55\u53ca\u5176\u6f5b\u5728\u5f71\u97ff\u7684\u9810\u671f\u548c\u5224\u65b7\uff0c\u4e14\u50c5\u4ee3\u8868\u622a\u81f3\u9673\u8ff0\u767c\u8868\u4e4b\u65e5\u7684\u89c0\u9ede\u3002\u7121\u8ad6\u51fa\u73fe\u65b0\u4fe1\u606f\u3001\u672a\u4f86\u4e8b\u4ef6\u6216\u5176\u4ed6\u60c5\u6cc1\uff0c\u4e9e\u76db\u91ab\u85e5\u5747\u7121\u7fa9\u52d9\u66f4\u65b0\u6216\u4fee\u8a02\u4efb\u4f55\u524d\u77bb\u6027\u9673\u8ff0\u3002","breadcrumb":{"@id":"https:\/\/pingtungtimes.com.tw\/?p=378515#breadcrumb"},"inLanguage":"zh-TW","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pingtungtimes.com.tw\/?p=378515"]}]},{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/?p=378515#primaryimage","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Ascentage_APAC_Logo-12.jpg","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/Ascentage_APAC_Logo-12.jpg","width":400,"height":150},{"@type":"BreadcrumbList","@id":"https:\/\/pingtungtimes.com.tw\/?p=378515#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u9996\u9801","item":"https:\/\/pingtungtimes.com.tw\/"},{"@type":"ListItem","position":2,"name":"\u30102025 ASH\u3011\u4e9e\u76db\u91ab\u85e5\u8010\u7acb\u514b\u00ae\u591a\u9805\u7814\u7a76\u5165\u9078\uff0cPOLARIS-1\u7814\u7a76\u6578\u64da\u9996\u6b21\u767c\u5e03"}]},{"@type":"WebSite","@id":"https:\/\/pingtungtimes.com.tw\/#website","url":"https:\/\/pingtungtimes.com.tw\/","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","description":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831PingtungTimes\uff0c\u6700\u95dc\u5fc3\u5728\u5730\u7684\u5a92\u9ad4","publisher":{"@id":"https:\/\/pingtungtimes.com.tw\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pingtungtimes.com.tw\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"zh-TW"},{"@type":"Organization","@id":"https:\/\/pingtungtimes.com.tw\/#organization","name":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831","url":"https:\/\/pingtungtimes.com.tw\/","logo":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/","url":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","contentUrl":"https:\/\/pingtungtimes.com.tw\/wp-content\/uploads\/2023\/02\/logo-150.png","width":150,"height":150,"caption":"\u5c4f\u6771\u6642\u5831\u96fb\u5b50\u5831"},"image":{"@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pingtungnews"]},{"@type":"Person","@id":"https:\/\/pingtungtimes.com.tw\/#\/schema\/person\/683b937f29ec1537972f6c41e22a2cf3","name":"\u7f8e\u901a\u793e","image":{"@type":"ImageObject","inLanguage":"zh-TW","@id":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6c21e24ce33ca5d4572e343395adac2bbef44ff7035a74ea2cab2443c7f0a5f3?s=96&d=blank&r=g","caption":"\u7f8e\u901a\u793e"},"url":"https:\/\/pingtungtimes.com.tw\/?author=16"}]}},"_links":{"self":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/378515","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=378515"}],"version-history":[{"count":0,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/378515\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=\/wp\/v2\/media\/378516"}],"wp:attachment":[{"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=378515"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=378515"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pingtungtimes.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=378515"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}